Neurology and Neurosurgery: Recent Episodes
ReachMD
Guest: Nicholas J. Silvestri, MD, FAAN
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD, FAAN
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD, FAAN
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD, FAAN
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD, FAAN
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD, FAAN
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD, FAAN
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD, FAAN
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD, FAAN
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Guest: Nicholas J. Silvestri, MD, FAAN
Guest: James F. Howard, Jr, MD
The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.
Host: John Russell, MD
Guest: Noel Dasgupta, MD, FACC
Guest: Sami Khella, MD
Amyloidosis, often unrecognized, misdiagnosed, and either inappropriately treated or undertreated, is a collection of diseases caused by the misfolding of proteins that aggregate into insoluble amyloid fibrils and deposit in tissues. There are two prominent forms of amyloidosis misfolding of light chain proteins (AL amyloidosis) and transthyretin protein misfolding (ATTR amyloidosis). In this program, two experts in amyloidosis, cardiologist Dr. Noel Dasgupta and neurologist Dr. Sami Khella, will explain the pathophysiology of amyloidosis, describe the prognosis for patients, discuss timely patient screening and diagnostic testing, and provide updated treatment options.
Host: Jennifer Caudle, DO
Guest: Lori Guyton, MD
Guest: Douglas Scharre, MD
Our understanding of the mechanisms underlying Alzheimer’s disease is growing, and these advances can help inform diagnosis and management strategies. In fact, as our understanding of Alzheimer’s disease evolves, our strategies to diagnose and manage the disease are changing to focus on early diagnosis and intervention.1 Joining Dr. Jennifer Caudle to discuss our current understanding of disease progression as well as the impact and benefit of diagnosing Alzheimer’s disease early are Drs. Douglas Scharre and Lori Guyton. Dr. Scharre is the Director of the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin.
Reference:
- Atri A. The Alzheimer’s disease clinical spectrum: Diagnosis and management. Med Clin North Am. 2019;103:263-293.
© Eisai Inc. 2024. All Rights Reserved.
AD-M2123 November 2024
Host: Jennifer Caudle, DO
Guest: Lori Guyton, MD
Guest: Douglas Scharre, MD
As our understanding of Alzheimer’s disease continues to evolve, it’s critical to understand the clinical and pathologic changes underpinning Alzheimer’s disease as it may be able to help guide early diagnosis and clinically meaningful management decisions.1 That’s why Drs. Douglas Scharre and Lori Guyton speak with Dr. Jennifer Caudle about Alzheimer’s disease pathophysiology and how it translates to clinical practice. Dr. Scharre is a Professor of Clinical Neurology and Psychiatry as well as the Director for the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin.
Reference:
- Porsteinsson A, Isaacson R, Knox S, Sabbagh M, Rubino I. Diagnosis of early Alzheimer’s disease: Clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386.
© Eisai Inc. 2024. All Rights Reserved.
AD-M2130 November 2024
Guest: C. Brendan Montano, MD
Guest: Anton P. Porsteinsson, MD
Early diagnosis and management of agitation in Alzheimer’s disease (AAD) is part of a comprehensive treatment plan. How can you help caregivers recognize subtle signs of AAD to facility early treatment? Our experts have the answers you need!
Guest: John F. Brandsema, MD
As patients with Duchenne muscular dystrophy (DMD) age, their treatment regimens, considerations, and goals change. That’s why Dr. John Brandsema is here to talk about how we can best treat and support patients with DMD throughout their entire care journey. Dr. Brandsema is the Neuromuscular Section Head at the Children’s Hospital of Philadelphia.
Guest: John F. Brandsema, MD
Between 60 and 70 percent of patients with Duchenne muscular dystrophy (DMD) also have a diagnosable neurobehavioral phenotype like autism, ADHD, and anxiety. Here to talk about these common neurobehavioral issues in patients with DMD and how we can manage them is Dr. John Brandsema, Neuromuscular Section Head at the Children’s Hospital of Philadelphia.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John F. Brandsema, MD
The gene therapy delandistrogene moxeparvovec was recently approved for patients with Duchenne muscular dystrophy (DMD) who are at least 4 years old. This expanded approval is based on the efficacy and safety results from the EMBARK trial. Joining Dr. Charles Turck to break down those key findings and the implications of this advancement in DMD treatment is Dr. John Brandsema. Dr. Brandsema is the Neuromuscular Section Head at the Children’s Hospital of Philadelphia, where one of the clinical trials for this gene therapy took place.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jasmohan Bajaj, MD
Around 50 percent of people with cirrhosis have hepatic encephalopathy, which means some kind of brain dysfunction. As these patients age, it gets more and more difficult to differentiate between hepatic encephalopathy and dementia, which is why two recent studies sought to uncover how many patients with dementia have undiagnosed cirrhosis. According to the findings, the rate of undiagnosed cirrhosis and hepatic encephalopathy could be as high as 10‒13 percent. Joining Dr. Charles Turck to share further details about the studies, findings, and implications is Dr. Jasmohan Bajaj, Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Dr. Robert J. Shmookler Reis, PhD
Guest: Dr. Srinivas Ayyadevara, PhD
Numerous factors could predispose patients to the progression of mild cognitive impairment or dementia and Alzheimer’s disease. Fortunately, a recent study found that a cholesterol-lowering medication called ezetimibe might help reduce the risk of Alzheimer’s disease progression and related dementias. To learn about the methods and key findings of the study, join Dr. Charles Turck as he takes a deep dive with Dr. Robert Reis, Professor and Researcher at the University of Arkansas for Medical Sciences’ Institute on Aging College of Medicine and Research Career Scientist at the Central Arkansas Veterans Healthcare System’s Geriatric Research, Education and Clinical Center, and Dr. Srini Ayyadevara, Associate Professor at the UAMS Institute on Aging College of Medicine and is a Research Health Scientist at the Central Arkansas VA’s GREC Center.
Host: Ashley Baker, MSN, PMHNP
Guest: Istvan Mody, PhD
The objective of this study around Alzheimer’s disease was to enhance oscillations in laying down memory traces and cognition. Using mice, the human APOE 4 gene was inserted into them, so they replicated similar events that take place in Alzheimer’s patients, and other mice were treated with DDL-920. The hope is to move on to human patients and to have a big impact on improving Alzheimer’s patient's life, cognition, and memory. To learn more, join Psychiatric Nurse Practitioner Ashley Baker as she speaks with Dr. Istvan Mody, Professor of Neurology and Physiology at UCLA Health and recipient of the J. Allyn Taylor International Prize in Medicine in 2018.
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Brain metastases are a frequent complication of lung cancer, which is why the TROPION-Lung05 trial evaluated the intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced metastatic non-small cell lung cancer (NSCLC). According to the data, Dato-DXd demonstrated intracranial efficacy and equivalent safety between patients who had brain metastases and those who did not. Joining Dr. Jacob Sands to discuss these findings is lead investigator and thoracic medical oncologist Dr. Aaron Lisberg.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nadia Merchant, MD
Guest: Melody Shi, MD
Guest: Despoina Galetaki, MD
Steroids are one of the main treatments for patients with Duchenne muscular dystrophy (DMD), but prolonged steroid use can come with many endocrine side effects, like weight gain, insulin resistance, and adrenal insufficiency. To learn more about these endocrine complications and surveillance, a recent survey was conducted, and here to share the results with Dr. Charles Turck are study authors Drs. Nadia Merchant, Melody Shi, and Despoina Galetaki.
Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Professor Sir John Hardy
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Professor Sir John Hardy
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Professor Sir John Hardy
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Professor Sir John Hardy
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Professor Sir John Hardy
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Host: Marwan Noel Sabbagh, MD, FAAN, CCRI
This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.
Guest: Marwan Noel Sabbagh, MD, FAAN, CCRI
Autophagy through sigma-1 receptor activation is a novel mechanism of action (MOA) in development for the treatment of Alzheimer’s disease. Join Dr. Marwan Noel Sabbagh as he breaks down this new MOA and recent clinical trial data.
Host: Perry Shieh, MD, PhD
Explore this on-demand webcast for an in-depth expert presentation and case discussion. This educational initiative is designed to help neurologists enhance their clinical approach by providing individualized, evidence-based care for adult SMA patients. Gain insights into the latest treatment options, safety and efficacy data, and effective patient communication strategies. Equip yourself with the knowledge to meet the unique clinical and psychosocial needs of adults with SMA and improve patient outcomes.
Guest: Phillip H. Kuo, MD, PhD
One of the major changes that's occurred very recently in the field of neurodegenerative disease and Alzheimer's disease, specifically, are the recently approved antibody therapies that remove amyloid from the brain, which is one of the culprit proteins in Alzheimer's disease. To learn more about this presentation from SNMMI 2024, join Dr. Phillip Kuo, Professor of Medical Imaging, Medicine, and Biomedical Engineering at the University of Arizona.
Host: Ashley Baker, MSN, PMHNP
Guest: Kathleen Nadeau, PhD
Girls and women with ADHD are often underdiagnosed and undertreated compared to boys and men, which puts them at risk of serious issues like unplanned pregnancies, cigarette smoking, and even anxiety and depression. To help us better identify and manage girls and women with ADHD, psychiatric nurse practitioner Ashley Baker speaks with Dr. Kathleen Nadeau, Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.
Guest: Kathleen Nadeau, PhD
It’s important to be aware of the different ways ADHD impacts girls and women compared to boys and men, which is why Dr. Kathleen Nadeau is here to help shed light on those differences. Dr. Nadeau is the Founder and Clinical Director of the Chesapeake Center for ADHD Learning and Behavioral Health in Bethesda, Maryland.
Host: Valeria Caso, MD, PhD
Guest: Ashkan Shoamanesh, MD
How can you improve long-term secondary stroke prevention in patients with a history of noncardioembolic ischemic stroke or transient ischemic attack (TIA)? An understanding of how to apply emerging clinical trial data is critical, as is the evaluation of potential alternative agents that could expand the therapeutic options for these patients. In this activity, our expert faculty will add to your knowledge by reviewing the coagulation cascade and the relevance of inhibiting factors XI and XIa in stroke management.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kay Davies, PhD, DBE FMedSci FRS
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by the progressive loss of muscle, and it primarily occurs in young boys. And since there’s currently no cure, recent therapeutic advancements are aimed at improving symptoms and patient’s quality of life. Dive in to review the therapeutic landscape with Dr. Charles Turck as he’s joined by Dr. Kay Davies, who’sDr Lee's Professor of Anatomy Emeritus at the University of Oxford.
Host: Robert Shin, MD, FANA, FAAN
Guest: Enrique Alvarez, MD, PhD
Guest: Jiwon Oh, MD, PhD, FRCPC
The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease. Though such advancements are welcome, they continue to raise new questions about how to optimize management for individual patients. In this program, real clinicians who treat MS pose their most pressing clinical questions to an expert panel. These specialists then provide their best answers through literature and their own clinical experience.
Guest: John Berk, MD
Guest: Sami Khella, MD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: Sami Khella, MD
Guest: Marcia Waddington-Cruz, MD, PhD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: Sami Khella, MD
Guest: Marcia Waddington-Cruz, MD, PhD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: Sami Khella, MD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: Sami Khella, MD
Guest: Marcia Waddington-Cruz, MD, PhD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: John Berk, MD
Guest: Noel Dasgupta, MD, FACC
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: John Berk, MD
Guest: Sami Khella, MD
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Guest: Noel Dasgupta, MD, FACC
Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the complexities of ATTRv-PN, differentiate familial vs wild-type forms, identify red flags for early detection, and review the latest diagnostic tools. Discover promising new therapies and what the future may hold for ATTRv-PN treatment. Join the experts and equip yourself to effectively manage this challenging disease and improve patient outcomes.
Host: Omer Abdul Hamid, MD
Guest: Nancy Kuntz, MD
Guest: Migvis Monduy, MD
There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.
Host: Stephen Krieger, MD
Guest: Tirisham Gyang, MD
Guest: Augusto Miravalle, MD, FAAN
New strategies for early intervention in multiple sclerosis (MS) are focusing on progression independent of relapse. These strategies include incorporation of high-efficacy disease modifying therapies in the early stages of MS coupled with effective management of treatment-related adverse events. Join Drs. Stephen Kreiger, Tirisham Gyang, and Augusto Miravalle for a lively, case-based exchange that will provide key ideas to take back into the clinic.
Host: Heidi M. Munger Clary, MD, MPH
Guest: Jay Salpekar, MD, FANPA
A crucial aspect of epilepsy care that often goes underappreciated is the intersection of epilepsy and depression. Join Drs. Munger Clary and Salpekar, leading experts in the field, as they raise awareness about the high prevalence of comorbid mental health disorders, particularly depression, among epilepsy patients. Together, they explore the bidirectional relationship between epilepsy and depression, emphasizing the importance of early detection and comprehensive treatment. They’ll also cover implantable therapies, specifically vagal nerve stimulation devices, as potential tools to manage both epilepsy and depression.
Host: Ashkan Shoamanesh, MD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Manesh R. Patel, MD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Valeria Caso, MD, PhD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Mike Sharma, MD, MSc, FRCPC
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Greg Albers, MD
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Adrian R. Parry-Jones, FRCP, PhD
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Stuart Connolly, MD, FRCPC
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Greg Albers, MD
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Stuart Connolly, MD, FRCPC
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Stuart Connolly, MD, FRCPC
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Natalie Kreitzer, MD, MS
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Rhonda Cadena, MD, FNCS, FCCM
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: Jessica Ailani, MD
Guest: Dawn C. Buse, PhD
Half of the women in the US with migraine are never diagnosed. Of those who are, the journey to effective treatment may last a decade or longer. But newer and more effective targeted treatments are beginning to make a difference. Join Drs. Jessica Ailani and Dawn Buse as they discuss a novel approach to managing migraine and interview a patient whose migraine journey is unfortunately one traversed by many women.
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Michael J. Thorpy, MD
Guest: Anne Marie Morse, DO
Half of children who develop narcolepsy do so before age 16. However, the majority do not get diagnosed in childhood. In fact, many children are misdiagnosed and, as a result, are medically treated for conditions they do not have. Join Drs. Thorpy and Morse as they delineate the differences between adult and pediatric narcolepsy and offer strategies to optimize treatment adherence and outcomes in children.
Host: Clete A. Kushida, MD, PhD
Guest: Michael J. Thorpy, MD
Three different sodium oxybate formulations are available for the management of narcolepsy with/without cataplexy. While they are equally efficacious, there are differences such as dosing that require shared decision- making between patient and clinician to select the right formulation for each patient. Join Drs. Kushida and Thorpy as they share their approach to making the right treatment decision for each patient, one that includes ensuring patient preferences are considered.
Host: Eliza B. Geer, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Eliza B. Geer, MD
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Eliza B. Geer, MD
Guest: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Kevin C.J. Yuen, MD
Guest: Susan L Samson, MD, PhD, FRCPC, FACE
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Eliza B. Geer, MD
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Kevin C.J. Yuen, MD
Guest: Eliza B. Geer, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Kevin Trice, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Kevin Trice, MD
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Matthew Davis, MD
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
Host: Diana Kimmel
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Kevin Trice, MD
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Matthew Davis, MD
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Kevin Trice, MD
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Stephen Silberstein, MD
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
Host: Stewart J. Tepper, MD, FAHS
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
Host: Stephen Silberstein, MD
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
Host: Stephen Silberstein, MD
Host: Stewart J. Tepper, MD, FAHS
This program focuses on preventative treatment strategies for patients with chronic migraines. Its purpose is to improve healthcare providers’ understanding of the how excessive use of over-the-counter (OTC) and prescription pain medications can negatively affect the quality of life for those with chronic migraines. The program also covers the most up-to-date evidence-based treatment guidelines and emphasizes patient-centered approaches when using preventative therapies for managing chronic migraines. Additionally, the program explores the latest advancements in preventative treatments and emerging options for individuals with chronic migraines.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Craig Chepke, MD, FAPA
From a women's mental health pre-conference to new mechanisms of action coming into psychiatry for the first time in decades, there’s a lot to look forward to at this year’s meeting. Join Dr. Mary Katherine Cheeley as she gets more highlights from Dr. Craig Chepke, Medical Director of Excel Psychiatric Associates and Psych Congress 2023 Scientific Advisor.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Eoin Flanagan, MB, BCh
For the first time since 2008, the International Advisory Committee on Clinical Trials in Multiple Sclerosis have made updates to their diagnostic guidelines for patients with suspected multiple sclerosis (MS). Joining Dr. Andrew Wilner to discuss these key updates is Dr. Eoin Flanagan, the Chair of the Division of Multiple Sclerosis and Autoimmune Neurology at the Mayo Clinic in Rochester, Minnesota.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: John Corboy, MD, MA
Disease-modifying therapies (DMTs) reduce disease activity and slow the progression of disability in multiple sclerosis. But there were some challenges that came out of this recent study. To discuss the findings from this trial, Dr. Andrew Wilner is joined by Dr. John Corboy, Professor of Neurology and the Director of the Rocky Mountain MS Center at the University of Colorado.
Guest: Sergio Baranzini, PhD
A recent study was designed by the International Multiple Sclerosis Genetics Consortium with the goal in mind to find out whether the severity of multiple sclerosis (MS) could be influenced by genetics. Dive in with Dr. Sergio Baranzini, Distinguished Professor of Neurology at the University of California San Fransico and Co-Senior Author of the study.
Guest: James Galvin, MD, MPH, FANA
Guest: Jon Toledo, MD, PhD
Guest: Charles P. Vega, MD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this program employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity focuses on the role of primary care physicians (PCPs) in the monitoring, recognition, and management of ARIA. This includes an overview of baseline needs surrounding Aβ-DMT, potential presentations of ARIA in primary care, courses of action that may be needed regarding its evaluation/treatment, and communication throughout care.
Note that the core activity is supplemented by an
Host: Jennifer Caudle, DO
Guest: Michelle Kincaid, MD
The largest study to date on 4F-PCC was conducted as an FDA postmarketing requirement in partnership between Kaiser Permanente and CSL Behring. The purpose of this long-term study was to compare the 45-day risk of thromboembolic events and all-cause mortality in adults with warfarin-associated major bleeding after treatment with KCENTRA®, Prothrombin Complex Concentrate (Human), or plasma. Take a deep dive into the data with Dr. Jennifer Caudle as she speaks with Dr. Michelle Kincaid, Trauma Surgeon and Director of Surgical Critical Care at Ohio Health Grant Medical Center in Columbus.
Host: James Galvin, MD, MPH, FANA
Guest: Jon Toledo, MD, PhD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this program employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a seriesof six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity focuses on the role of neurology clinicians including when to raise clinical suspicion of ARIA in the clinic, how to evaluate suspected ARIA, and what courses of action may be needed to treat/manage ARIA should it occur.
Note that the core activity is supplemented by an interactive clinical summary …
Host: Jerome Lisk, MD
Guest: Santosh Kumar, PhD
In an effort to examine the correlation between HIV-induced aging and Alzheimer’s disease in the United States population, a team of researchers at the University of Tennessee Health Science Center are working to develop a novel drug delivery system. To learn more, Dr. Jerome Lisk is joined by Dr. Santosh Kumar to discuss his current research and the effects it could have on future treatment approaches for HIV-induced aging and Alzheimer’s disease. Dr. Kumar is a Professor in the Department of Pharmaceutical Science at the University of Tennessee.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Ashley Baker, MSN, PMHNP
Before COVID-19, HCPs and patients had a lot of access to virtual healthcare, but it wasn’t being fully utilized. So what should we know about the ongoing use of telemedicine and the Ryan Haight Act? Take a deep dive with Dr. Mary Katherine Cheeley as she speaks with Ashley Baker, Psychiatric Nurse Practitioner and Co-Founder of Ascend Integrative Medicine in Boston, MA.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Avindra Nath, MD
Researchers from the National Institutes of Health (NIH) found that 100 percent of the participants in this study had fatigue and experienced cognitive difficulties. So what can we learn from this new research to help us diagnose and treat patients with disabling neurological symptoms after they had COVID-19? To discuss the findings, Dr. Charles Turck is joined by Dr. Avindra Nath, Clinical Director of the National Institute of Neurological Disorders and Stroke.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Priscilla Brastianos, MD
Brain metastases are the most common type of brain tumor, and unfortunately, prognosis is still limited and can range from a few months to a few years. However, the next-step approaches look promising for improving patient outcomes. Dive in with Dr. Charles Turck as he speaks with Dr. Priscilla Brastianos, Associate Professor of Medicine at Harvard Medical School and the Director of the Central Nervous System Metastasis Center at Massachusetts General Hospital.
Host: James Galvin, MD, MPH, FANA
Guest: Gloria Chiang, MD
Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity focuses on the role of emergency medicine clinicians in the recognition and management of ARIA. This includes an overview of how ARIA may present to the emergency department and what courses of action to treat/manage ARIA may be needed from the hospital care team.
Host: James Galvin, MD, MPH, FANA
Guest: Gloria Chiang, MD
Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Guest: Charles P. Vega, MD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity finishes out the series by first providing an abbreviated outline of what has been addressed across activities 1-5 followed by a multidisciplinary discussion of questions and considerations that may impact the team-based execution of discussed strategies.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lokesh Shahani, MD, PhD, MPH, FACP, FASAM
Due to their clinical overlap, distinguishing between neurocognitive and psychiatric disorders can be challenging, but an accurate diagnosis is crucial for timely assessment and treatment. Find out how we can better identify and treat complex neurocognitive disorders such as Alzheimer's disease and other forms of dementia with Dr. Charles Turck and Dr. Lokesh Shahani, Associate Professor of Psychiatry and Behavioral Sciences at UT Health Houston McGovern Medical School who presented on this exact topic at the 2023 APA Annual Meeting.
Host: Jerome Lisk, MD
Guest: Rajesh Rajagopalan Tampi, MBBS, MS, DFAPA
Behavioral and psychological symptoms of dementia (BPSD) refers to a group of noncognitive symptoms that commonly occur in patients with dementia. While data shows efficacy for treatment modalities for these symptoms and behaviors, the use of psychotropic medications has been met with controversy due to their adverse effects. Tune in to hear Dr. Rajesh Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine, discuss how we can address those controversies while providing optimal care for our patients, which was the focus of his presentation at the 2023 American Psychiatric Association Annual Meeting.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Dominique Higgins, MD, PhD
Glioblastoma is the most common type of brain tumor while also being one of the most aggressive cancers in adults. So what do we need to know about ferroptosis? Dive in with Dr. Andrew Wilner as he’s joined by Dr. Dominique Higgins, Assistant Professor of Neurosurgery at the University of North Carolina School of Medicine.
Host: Jerome Lisk, MD
Guest: Rajesh Rajagopalan Tampi, MBBS, MS, DFAPA
Here to share some of the key presentations at the 2023 American Psychiatric Association (APA) Annual Meeting is Dr. Raj Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine.
Host: Jerome Lisk, MD
Guest: Rajesh Rajagopalan Tampi, MBBS, MS, DFAPA
Find out what previous and ongoing clinical trials are telling us about the use of cannabinoids to treat behavioral and psychological symptoms of dementia (BPSD) with Dr. Jerome Lisk and Dr. Raj Tampi, Professor and Chairman of the Department of Psychiatry at Creighton School of Medicine.
Host: James Galvin, MD, MPH, FANA
Guest: Gloria Chiang, MD
Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Guest: Charles P. Vega, MD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This six-part series features distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This first activity focuses on the rise of amyloid-targeting DMT and the subsequent key features of ARIA that impact all specialties.
Guest: Daniel Kremens, MD, JD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Rajesh Pahwa, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Daniel Kremens, MD, JD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Host: Daniel Kremens, MD, JD
Guest: Rajesh Pahwa, MD
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Host: Daniel Kremens, MD, JD
Guest: Rajesh Pahwa, MD
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Host: Nilika Singhal, MD
Guest: M. Scott Perry, MD
Guest: Elizabeth Anne Thiele, MD, PhD
Lennox-Gastaut syndrome and Dravet syndrome are 2 rare epileptic disorders with a pediatric onset. They‘re often refractory to therapy and have significant side effects due to polytherapy. Listen in as Drs. Nilika Singhal, Elizabeth Thiele, and M. Scott Perry discuss treatment options and how you can lessen the impact of polypharmacy on your patients.
Host: Nilika Singhal, MD
Guest: M. Scott Perry, MD
Guest: Elizabeth Anne Thiele, MD, PhD
Lennox-Gastaut syndrome and Dravet syndrome are 2 rare epileptic disorders with a pediatric onset. They‘re often refractory to therapy and have significant side effects due to polytherapy. Listen in as Drs. Nilika Singhal, Elizabeth Thiele, and M. Scott Perry discuss treatment options and how you can lessen the impact of polypharmacy on your patients.
Host: Charles P. Vega, MD
Guest: George Grossberg, MD
This Expert Exchange webcast is designed to improve clinicians’ ability to treat agitation in patients with Alzheimer’s dementia.
Host: Charles P. Vega, MD
Guest: Thomas W. Heinrich, MD
This Expert Exchange webcast is designed to improve clinicians’ ability to define, identify and assess agitation in Alzheimer’s dementia.
Guest: Shibeshih Belachew, MD PhD
Host: Charles Turck, PharmD, BCPS, BCCCP
Technology is advancing exponentially, and this has been more evident than ever in the field of medicine. In fact, biotech and pharmaceutical companies are bringing biology and technology together to better meet patient needs across a range of specialties. So what are the latest research and initiatives in digital health that are working towards a future of more personalized medicine for patients with multiple sclerosis (MS)? Joining Dr. Turck to share insights on digital health innovations in MS care is Dr. Shibeshih Belachew, Head of Science at Biogen Digital Health.
© 2023 Biogen. All rights reserved.
Host: Robert Shin, MD, FANA, FAAN
Guest: Jiwon Oh, MD, PhD, FRCPC
Guest: Enrique Alvarez, MD, PhD
Over the past several years, the image of MS has been changing from distinct categories of disease to a complicated spectrum of interwoven pathologies. As this knowledge evolves, so do approaches to prognosticating, monitoring, and responding to disease. With many markers of progression still under investigation and therefore not included in modern guidelines, MS clinicians are left on their own to decide which factors should hold the most weight in influencing clinical decisions. In this “debate-themed” symposium originally held in conjunction with the 2023 ACTRIMS Forum, Drs Shin, Alvarez, and Oh advocate for their preferred disease indicators and why they are the future of successful MS disease management. In the absence of professional guidelines, these expert perspectives may deepen the understanding of exactly how and why these factors should be considered, improving clinicians’ ability to navigate and optimize available tools and strategies for their own patients.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Selim Benbadis, MD
It may be challenging for a family member to take a video on their cell phone while a patient is having a seizure. However, they have been deemed useful in helping physicians establish a history of seizures in epileptic patients. So should clinicians consider this as a reimbursable diagnostic tool? Joined by the physician who posed this question in a recent article for the journal Neurology Clinical Practice, Dr. Andrew Wilner speaks with Dr. Selim Benbadis, Professor of Neurology and the Director of the Comprehensive Epilepsy Program at the University of South Florida.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John F. Brandsema, MD
Spinal muscular atrophy (SMA) is a rapidly progressive disease, but current treatment options might help us slow its progression. Dr. Charles Turck explores these treatment options with Dr. John Brandsema from the Perelman School of Medicine at the University of Pennsylvania.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Nassim Rad, MD
Guest: Vanessa Battista, RN
Collaborative care plays an important role in treating patients is spinal muscular dystrophy (SMA). To learn more about this, Dr. Andrew N. Wilner is joined by Drs. Vanessa Battista and Nassim Rad to share their insights on team structures and collaborative care for SMA.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: David Weisman, MD
Alzheimer’s disease is the most common form of dementia, and symptoms become more severe over time. In fact, it’s the leading cause of disability and poor health in older adults. And although there’s no cure, a new medication called lecanemab recently received accelerated approval by the US Food and Drug Administration. So what might this new development mean for the 6 million Americans living with this debilitating disease? Find out as Dr. Andrew Wilner speaks with fellow ReachMD host Dr. David Weisman, who’s also the Director of Clinical Research at Abington Neurological Associates.
Host: Danielle Becker, MD, MS, FAES
Host: Ahmed Abdelmoity, MD
Guest: Deborah Holder, MD
Guest: John Stern, MD
Vagus nerve stimulation (VNS) therapy is an add-on neuromodulation treatment designed for adults and children diagnosed with drug-resistant epilepsy (DRE). The device delivers mild pulses to the brain through the vagus nerve to help prevent seizures before they start and help stop them if they do. Join Drs. Danielle Becker, John Stern, Deborah Holder, and Ahmed Abdelmoity as they discuss best practices for initiating, titrating, and dosing adult and pediatric patients to optimize outcomes.
Host: Bradley Torphy, MD
Learn more about the efficacy and other clinical data for this preventive migraine treatment option. Dr. Brad Torphy highlights clinical data on this treatment option.
Host: Wade Cooper, DO
For patients with chronic or episodic migraine, what treatment options should we consider? To help answer that question, Dr. Wade Cooper discusses a treatment option for migraine.
Host: Sara W. Koblitz
Guest: Michael J. Thorpy, MD
While most clinicians are aware of a drug being either “approved” or “not approved” by the FDA, many are not familiar with the term “tentative approval.” Leading experts, attorney Sara Koblitz, JD, and Dr. Michael Thorpy, review the FDA approval process, explore how “tentative approval” is currently impacting treatment in the field of sleep medicine, and discuss how “non-drug” issues are related to delayed FDA approval. Review the latest safety and efficacy pivotal trial data associated with once-nightly sodium oxybate and find out if we’re truly on the cusp of a new awakening in sleep medicine.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Bruce Hermann, PhD
Guest: Shlomo Shinnar, M.D., Ph.D.
In hopes of learning more about how the brain changes due to aging in patients with childhood-onset epilepsy, a new study was funded that may suggest some interesting findings. So what do we need to know from the results of this study? To dive into this topic, Dr. Andrew Wilner is joined by Dr. Bruce Hermann, Emeritus Professor at the University of Wisconsin School of Medicine and Public Health, and Dr. Shlomo Shinnar, Professor Emeritus of Neurology and Pediatrics at Albert Einstein College of Medicine.
Host: Jerome Lisk, MD
Guest: Katherine Longardner, MD
A recent five-year observational study aimed to determine the impact of individual autonomic domains that were associated with Parkinson’s disease. So what were the key findings of this study? Join Dr. Jerome Lisk as he welcomes Dr. Katherine Longardner, Assistant Professor of Neurosciences at UC San Diego Health, to discuss this trial in-depth.
Guest: Matt Birnholz, MD
Could an oral compound represent a new class of psychotropic agent with a non-D2-receptor binding mechanism of action for the treatment of psychosis in schizophrenia? That’s what the authors of a recent study wanted to find out, and it’s what Dr. Matt Birnholz explores in this Audio Abstract.
To review the full abstract, please click here.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Craig Chepke, MD, FAPA
Trace amine-associated receptor type 1 (TAAR1) is thought to be the most important receptor for treating neuropsychiatric disorders, and it could provide more benefits and medications to patients with these illnesses. To discover more, Dr. Charles Turck, is joined by Dr. Craig Chepke, Clinical Assistant Professor of Psychiatry at SUNY Upstate Medical University.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Philip D. Harvey, PhD
The current therapies we have available for schizophrenia are very effective at reducing psychotic symptoms in most patients, but for about 30 percent of patients, adverse events and suboptimal treatment responses can take a heavy toll. Could emerging therapies help us address these unmet needs? Learn more about the efficacy and tolerability limitations of current treatment options and what’s on the horizon with Dr. Charles Turck and Dr. Philip Harvey from the University of Miami Miller School of Medicine.
Host: Jose Rubio, MD
If clinicians can better understand the pathophysiology of schizophrenia, it could lead to more therapeutic options for this illness. So which potential mechanisms could be involved in its pathophysiology and in the discovery of more treatments for schizophrenia? Learn more about this illness with Dr. Jose Rubio, Assistant Professor at the Institute for Behavioral Science at the Feinstein Institutes for Medical Research.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Walter Koroshetz, MD
Amyotrophic lateral sclerosis (ALS) is a rare neurogenerative disease, and organizations including the FDA and NIH are working to accelerate potential therapies. What’s on the horizon for the treatment landscape? Mario Nacinovich joins Dr. Walter Koroshetz, who is the Director of the National Institute of Neurological Disorders and Stroke, to explore these new developments.
Host: Maria Fleseriu, MD, FACE
Guest: Irina Bancos, MD
Cushing’s disease is complex, and individualized approaches require the consideration of many patient factors. You and your patient also need to know what to expect in terms of therapeutic response and speed of recovery. Tune in as Drs. Maria Fleseriu and Irina Bancos address these challenges and more!
Host: Maria Fleseriu, MD, FACE
Guest: Irina Bancos, MD
Cushing’s disease is complex, and individualized approaches require the consideration of many patient factors. You and your patient also need to know what to expect in terms of therapeutic response and speed of recovery. Tune in as Drs. Maria Fleseriu and Irina Bancos address these challenges and more!
Host: Brian Barry
Guest: Amos Katz
Meet Susan and Mary, two real-world patients with different manifestations of progression in their RMS who were treated with the therapy option MAYZENT. So why was MAYZENT the appropriate choice for these patients, and how did they get started on this treatment option? Here to walk us through these two real-world patient cases and their perspectives on RMS management are Dr. Brian Barry and Dr. Amos Katz.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Deborah L. Korn, PsyD
Eye movement desensitization and reprocessing (EMDR) therapy is an interactive psychotherapy used to relieve stress and reduce symptoms of trauma. It is most commonly associated with the treatment of posttraumatic stress disorder (PTSD). But can this therapy also treat other stress-related disorders? To go into further detail, Dr. Charles Turck is joined by Dr. Deborah Korn, a clinical psychologist in private practice in Cambridge, Massachusetts and co-author of the book titled Every Memory Deserves Respect: EMDR, the Proven Trauma Therapy with the Power to Heal.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Marc E. Agronin, MD
Guest: Anton Porsteinsson, MD
From expert specialists like internists and geriatric neuropsychiatrists to the patient themselves and their loved ones, there are a lot of individuals involved in an Alzheimer’s disease care team. So what are some best practices for collaborating and coordinating a patient’s care across all members of the team? Joining Dr. Charles Turck to share their perspectives are Dr. Marc Agronin from MIND Institute and Dr. Anton Porsteinsson from the University of Rochester.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Sean Lawler, PhD
The STING protein is a novel treatment pathway for cancer. How might it affect our patients’ immune response to diseases such as brain cancer? Dr. Sean Lawler, an Associate Professor in the Department of Pathology and Laboratory Medicine at Brown University in Providence, Rhode Island. joins Dr. Andrew Wilner to explore the role of the STING pathway.
Host: Jennifer Caudle, DO
Guest: Sandra P. Reyna, MD
Spinal muscular atrophy (SMA) is a challenging rare disease that requires a diagnosis and access to treatment as early as possible. To help us understand the importance of early treatment, Dr. Sandra Reyna from Novartis Gene Therapies shares key considerations for optimizing outcomes and gives us some insight into available SMA treatment options, focusing on the gene therapy ZOLGENSMA.
© 2022 Novartis Gene Therapies, Inc.
US-ZOL-22-0129 08/22
Host: Jennifer Caudle, DO
Guest: Sandra P. Reyna, MD
Spinal muscular atrophy (SMA) is a challenging rare disease that requires a diagnosis and access to treatment as early as possible. To help us understand the importance of early treatment, Dr. Sandra Reyna from Novartis Gene Therapies shares key considerations for optimizing outcomes and gives us some insight into available SMA treatment options, focusing on the gene therapy ZOLGENSMA.
© 2022 Novartis Gene Therapies, Inc.
US-ZOL-22-0129 08/22
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Ahmed Zayed Obeidat, MD, PhD
Multiple sclerosis (MS) is a disabling disease that has challenged clinicians for decades. But developments in our understanding of the Epstein-Barr virus and emerging mRNA therapeutics may help us determine the root cause of MS—and develop a preventative treatment for it.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Marc E. Agronin, MD
Over five million Americans currently suffer from Alzheimer’s disease, and that number is only expected to double in the next several decades. But what do we first need to understand about its pathophysiology so that we can better care for our patients with Alzheimer’s disease? To give us an in-depth look, Dr. Charles Turck is joined by Dr. Marc Agronin, Chief Medical Officer for MIND Institute and President of the American Association for Geriatric Psychiatry.
Guest: Ahmed Zayed Obeidat, MD, PhD
The developments of mRNA therapeutics may change the way we treat neurodegenerative diseases. Here to provide insight on the role of these therapeutics and share what’s on the horizon is Dr. Ahmed Obeidat, Assistant Professor in the Department of Neurology at the Medical College of Wisconsin.
Guest: Benjamin Izar, MD
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Brain metastases are common in patients with advanced melanoma and are a leading cause of cancer-related death. However, little is known as to why melanoma spreads to the brain, but new research from Columbia University may provide some answers. To discuss this recent discovery, Dr. Andrew Wilner is joined by Dr. Benjamin Izar, Assistant Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.
Guest: Peter Whitehouse, MD, PhD
What kind of impact can Alzheimer’s disease have on our patients, their caregivers, and the healthcare system as a whole? Here to help answer that key question is Dr. Peter Whitehouse, Professor of Neurology at Case Western Reserve University.
Guest: Peter Whitehouse, MD, PhD
Although obtaining specific statistics about the prevalence of Alzheimer’s disease can be difficult, what we do know is that its prevalence is increasing worldwide. With that in mind, Dr. Peter Whitehouse from Case Western Reserve University joins us to help uncover the unmet needs of patients, caregivers, and clinicians.
Guest: Kostas Lyketsos
The risk of Alzheimer’s disease increases substantially with age. In fact, about one in three adults aged 85 and older have dementia. So how do we screen for it, and what kind of impact can early detection have on our patients? Here to break down essential cognitive screening strategies for Alzheimer’s disease is Dr. Constantine Lyketsos, the Elizabeth Plank Althouse Professor for Alzheimer’s Research and Chair of Psychiatry at the Johns Hopkins Bayview Medical Center.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Jason Barton, MD, PhD, FRCP(C)
Prosopagnosia, also known as face blindness, is a rare cognitive disorder. Joining Dr. Andrew Wilner to share his insights on this condition is Dr. Jason Barton, a Professor of Neurology, Ophthalmology and Visual Sciences, and Psychology at the University of British Columbia in Vancouver, Canada.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Sanjay Kumar, PhD
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy. Due to recent research from Florida State University, we might have a better understanding of the potential link between a specific protein and increased vulnerability to neurodegeneration among patients with this disorder. Dr. Andrew Wilner is joined by Dr. Sanjay Kumar, Professor of Biomedical Sciences and Neuroscience at Florida State University, to discuss this new discovery.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Julie Blatt, MD
Guest: Taizo Nakano, MD
PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.
The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.
Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.
Host: Jennifer Caudle, DO
Guest: Alireza Atri, MD, PhD
Guest: Sharon J. Sha, MD, MS
Alzheimer’s disease (AD) is a progressive, irreversible, neurodegenerative disease that significantly impacts the lives of patients and their families, as well as society. AD is typically diagnosed later in the disease course, limiting time for psychoeducation, interventional strategies, and planning. Additionally, this delayed diagnosis leads to inefficient or unnecessary care, as well as higher costs, and causes harm to individuals and society. That is why detecting AD early is critically important.
In the second part of this two-episode series, expert faculty will answer some of your questions pertaining to the early detection of AD.
If you haven’t viewed the first part of this series, you can view it here.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Nanette F. Santoro, MD
Tune out the noise and get to the heart of managing menopause and associated vasomotor symptoms. This program provides highlights from the 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Join Drs. Nanette Santoro and Lee Shulman as they dive into the latest research, which could alter your current practice patterns and help your patients cool off.
Host: Barry A. Singer, MD
Patients living with MS can experience hidden or invisible symptoms that may not be apparent to others but can affect how they feel and function. In this podcast, Dr. Barry Singer, the Director at the Multiple Sclerosis Center for Innovations in Care, and Rosario, a patient who has been living with MS for 10 years, discuss their clinical and personal experiences with MS, and the impact that MS can have on a patient's QoL.
In the 2-year AFFIRM pivotal trial: Relapsing MS patients received 300 mg TYSABRI every 28 days (n=627) or placebo (n=315). Patients with PPMS, SPMS, and PRMS were excluded.2,3
83% of patients taking TYSABRI had no sustained disability progression for 12 weeks vs 71% with placebo (primary endpoint: 17% vs 29%; p<0.001).2,3
Dr. Singer reviews the results of a recent publication from Hersh et al, which describes the effect of TYSABRI® (natalizumab) on various aspects of a patient’s QoL. In the study, 164 patients reported their experience after starting TYSABRI using a standard Quality of Life in Neurological Disorders (Neuro-QoL) assessment of 12 domains, which included anxiety, depression, positive affect and well-being, emotional and behavioral dyscontrol, stigma, cognitive function, sleep disturbance, fatigue, participation and satisfaction with social …
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Zachary Marcum, PharmD, PhD
Hypertension affects nearly half of adults in the United States and is associated with cognitive decline and dementia. A wide variety of antihypertensive medications are prescribed to millions of people to control blood pressure and prevent vascular dementia. Could it be that certain medications are better than others in preventing brain injury from chronic hypertension? Dr. Andrew Wilner is joined by Dr. Zachary Marcum, Associate Professor in the School of Pharmacy-University of Washington, to discuss his recent study investigating the association between certain hypertension medications and reduced cognitive impairment.
Host: Jennifer Caudle, DO
Guest: Alireza Atri, MD, PhD
Guest: Brad Dickerson, MD
Guest: Sharon J. Sha, MD, MS
Alzheimer’s Disease (AD) is a progressive disease that presents challenges when it comes to the early diagnosis and treatment of patients. That’s why this two-part series will help answer your specific questions while providing expert insights into these challenges.
In this first activity, a panel of esteemed faculty will examine the case of a patient who was diagnosed early with mild cognitive impairment (MCI) due to AD, prior to dementia. Using this patient case, faculty will delve into both the importance of early identification of AD and how to detect it early. The panel will then discuss the pathobiology of AD and potential treatments in development to target this pathology. Finally, the panel will explore current treatment options, including the appropriate use of anti-amyloid monoclonal antibody (mAb) treatment. Throughout this activity, we will gather questions from clinicians like you who care for patients living with dementia, and then in part two of this series, we will answer some of the questions generated from this first activity.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Jerome Lisk, MD
Guest: Peter Whitehouse, MD, PhD
Guest: Daniel George, MSc, PhD
Although there’s still no cure for Alzheimer’s disease, we’ve made great strides in understanding the tragic disease that affects more than 50 million people worldwide. So what are the latest updates in treating and alleviating this disease? To learn more about what’s new in Alzheimer’s disease research, Dr. Jerome Lisk speaks with Dr. Peter Whitehouse and Dr. Daniel George, co-authors of American Dementia: Brain Health in an Unhealthy Society.
Host: Jerome Lisk, MD
Guest: Peter Whitehouse, MD, PhD
The FDA’s recent approval of aducanumab for the treatment of Alzheimer’s disease has been met with a controversial response. So what do we need to know about this new drug and its potential to treat this progressive neurological disorder? Dr. Jerome Lisk is joined by Dr. Peter Whitehouse from Case Western Reserve University to break down the approval of this new drug and what it could mean for patients.
Host: Richard S. Isaacson, MD
Guest: Michael Weiner, MD
Are you familiar with available and developing tools for assessing Alzheimer’s disease (AD)? Correctly using these tools can lead to a vital earlier diagnosis which can improve outcomes for our patients. Tune in to hear Dr. Richard Isaacson and Dr. Michael Weiner take us through some of these assessment tools and they ways in which they can help us reach a true diagnosis of AD.
Host: Jacqueline Nicholas, MD, MPH
Ever had a multiple sclerosis (MS) patient who needed to start a DMT? Listen to Dr. Jacqueline Nicholas, System Chief of Neuroimmunology and Director of MS Research at Ohio Health, and Kim, a patient who has been living with MS for seven years, share their experiences with the treatment decision process, including benefit-risk considerations, treatment goals, and patient preferences. They talk about the process for starting and continuing treatment with TYSABRI® (natalizumab) and how Biogen Support Services can help.
Please see Important Safety Information, including Boxed Warning for PML, below.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Francesca Gilli, MS, PhD
What B-cell therapies are available for multiple sclerosis, and how do they fit into our treatment approach—in the context of the COVID-19 pandemic and beyond? Tune in to hear Dr. Charles Turck speak with Dr. Francesca Gilli about B-cell therapies.
Host: Hector O. Chapa, MD, FACOG
Guest: Ahmed Zayed Obeidat, MD, PhD
From therapeutic limitations to routes of administration, there’s a lot we need to keep in mind when selecting a treatment option for our patients with multiple sclerosis (MS). But it’s also just as important to consider patient-specific elements too, like their preferences and the socioeconomic factors affecting them. That’s why Dr. Ahmed Obeidat joins Dr. Hector Chapa to share these and other key treatment considerations in MS care.
Host: Hector O. Chapa, MD, FACOG
Guest: Ahmed Zayed Obeidat, MD, PhD
Unfortunately, not all of our patients with multiple sclerosis (MS) respond well to treatment. That’s why it’s critical to constantly assess their response to treatment and notice the signs that someone might be an efficacy-challenged patient. But what exactly are those signs, and how can you go about switching therapies? Joining Dr. Hector Chapa to share key strategies for managing efficacy-challenged patients with MS is Dr. Ahmed Obeidat.
Host: Jerome Lisk, MD
Guest: Ashok K. Shetty, PhD
Gulf War Illness is a chronic condition characterized by physiological and psychological symptoms, including cognitive dysfunction, memory problems, and depression. But what’s currently known about this debilitating condition that affects nearly 30 percent of Gulf War veterans? And how can we treat them? Find out with Dr. Jerome Lisk as he speaks with Dr. Ashok Shetty from Texas A&M University College of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Vikram V. Bhise, MD
Guest: Patty Bobryk, MHS, PT, MSCS, ATP
When it comes to managing multiple sclerosis (MS), it’s important to keep the patient at the center of care by learning about their unique goals as well as the sociodemographic and socioeconomic factors affecting them. So how can we learn more about our patients, and once we do, what evidence-based management strategies are available to us? Joining Dr. Charles Turck to share how we can tailor treatment plans for our patients with MS are Dr. Vikram Bhise and certified assistive technology practitioner Ms. Patty Bobryk.
Host: Paul Doghramji, MD
Guest: Vikram V. Bhise, MD
Shared decision-making is essential when it comes to caring for patients with multiple sclerosis. But what does its utilization actually look like in practice? To find out, Dr. Paul Doghramji speaks with Dr. Vikram Bhise, who shares a patient case in multiple sclerosis care that demonstrates how we can incorporate shared decision-making in practice.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Cheryl Carcel, MD, PhD
Although research suggests that women have a similar stroke risk as men, a new analysis has found that a very small percentage of participants in clinical trials investigating stroke treatments are female. So why are women underrepresented in these clinical trials, and what can be done to reverse this troubling trend? Joining Dr. Andrew Wilner to discuss strategies to improve the representation of women in stroke trials is Dr. Cheryl Carcel, neurologist and senior research fellow at the George Institute of Global Health.
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Host: Hector O. Chapa, MD, FACOG
Guest: Dani Dumitriu, MD, PhD
The COVID-19 pandemic has taken a toll on all patients, especially pregnant women. Here to walk us through her research on the pandemic's impact on the psychosocial health of mothers and the neurodevelopment of their fetuses is Dr. Dani Dumitriu, a pediatrician, neuroscientist, and pediatric environmental health scientist at Columbia University in New York.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Jose Rubio, MD
Schizophrenia is rarely a single-episode illness. In fact, 8 out of 10 patients will experience a relapse of symptoms after initial treatment. So how can we help reduce the frequency of relapse—and even non-adherence—among our patients with schizophrenia? To find out, Dr. Andrew Wilner is joined by Dr. Jose Rubio, psychiatrist at Long Island Jewish Medical Center and Assistant Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, to talk about the use of long-acting injectable (LAI) antipsychotics for schizophrenia treatment.
Host: John J. Russell, MD
Guest: R. Scott Turner, MD, PhD
Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. It is the most common cause of dementia worldwide and its’ prevalence continues to grow in part because of the aging world population. AD is characterized classically by two hallmark pathologies: β-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria including fluid and imaging biomarkers. Until recently, current therapies were limited to delaying cognitive decline in some patients, but not treating the underlying causes of the disease nor halting the progression of the disease. This program discusses recent advances in our understanding of the clinical evaluation for early and accurate diagnosis, newly approved and emerging disease-modifying therapies, as well as non-pharmacological strategies for the management of patients with AD.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Jennifer Caudle, DO
Guest: Vikram V. Bhise, MD
Pediatric multiple sclerosis (MS) occurs in more than 8,000 children in the United States alone, but there’s little data regarding these patients’ quality of life. That’s why Dr. Vikram Bhise recently conducted research to gain a better understanding of pediatric MS patients’ quality of life as they transition into adulthood. And now, Dr. Bhise joins Dr. Jennifer Caudle to share the results that were presented at the 2021 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.
Host: Jennifer Caudle, DO
Guest: Kevin Black, MD
Hallucinations and delusions cause a significant number of hospitalizations and nursing home admissions for our patients with Parkinson’s Disease. Listen to Dr Kevin Black share his approach to timely diagnosis and evidence-based management that can improve the daily lives of these patients and their caregivers.
Kevin Black, MDProfessor of Psychiatry, Neurology, Radiology, and Neurobiology
Washington University in St Louis School of Medicine
St Louis, Missouri
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Guest: Patty Bobryk, MHS, PT, MSCS, ATP
A multidisciplinary approach to multiple sclerosis (MS) is becoming more and more integral in practice as research continues to emerge on its significance. That’s why physical therapist Ms. Patty Bobryk is here to debrief us on some highlights from the rehabilitation track at the 2021 Consortium of Multiple Sclerosis Centers (CMSC) that focused on collaborative care.
Guest: Peter Goadsby, MD, PhD, DSc
Guest: Kathleen B. Mullin, MD
Women with migraine have unique needs that often remain undermanaged. Have you taken a critical look at the standard of care and how current treatment strategies have recently shifted? Groundbreaking research on the calcitonin gene-related peptide (CGRP) pathway has led to the development of new medications that act on the specific cascade of inflammatory response associated with migraine. Also called gepants, the CGRP receptor antagonists confer clinical benefit to patients who seek better control of their migraines.
Tune in to this Women’s Health 2021 program to hear our experts, Drs. Peter Goadsby and Kathleen Mullin, discuss the diagnosis of migraine with a focus on the recent evolution of acute and preventive treatment strategies and the role of gepants. Are you doing all you can to ensure that your patients’ needs are optimally addressed?
Host: Jerome Lisk, MD
Guest: Tissa Wijeratne MD PhD FRACP FRCP FAAN
Since the onset of the COVID-19 pandemic, researchers and clinicians alike have strived to address the mysteries surrounding the virus, including its long-term side effects on patients. So what we do need to know about the emerging syndrome pointing to COVID-19’s neurological and cognitive impacts? To find out, Dr. Jerome Lisk is joined by Dr. Tissa Wijeratne, the Director of the Department of Neurology and Stroke Services at the University of Melbourne, to talk about post-COVID-19 neurological syndrome.
Guest: Ann D. Bass, MD
Guest: Barry A. Singer, MD
Multiple sclerosis is a chronic inflammatory and neurodegenerative disease with a highly variable clinical course.1,2 Most patients who have relapsing-remitting multiple sclerosis (RRMS) will eventually transition to a secondary progressive course (SPMS).3 Patients with SPMS may live with significant impairment in physical and cognitive functions.4 Early identification of disease progression is important.2
Join Dr. Barry Singer from the MS Center for Innovations in Care at the Missouri Baptist Medical Center in St Louis, Missouri as well as Dr. Ann Bass from the Neurology Center of San Antonio in San Antonio, Texas as they share their real-world clinical perspectives on the management of patients with more progressed RMS, including those with aSPMS, and MAYZENT as a treatment option. Together, they will explore the following decision points:
- How to actively identify first signs of RMS progression
- A therapy for progressing RMS, including active SPMS
- What to consider when getting patients started on MAYZENT, a disease-modifying treatment
Host: Jason Freeman, MD, MBA
Guest: Scott Zamvil, MD, PhD
Our understanding of immunoglobins’ role in multiple sclerosis (MS) has evolved over the years. Joining Dr. Jason Freeman to share what we currently know about immunoglobins and immunology considerations for MS therapies and patient case scenarios is Dr. Scott Zamvil, Professor of Neurology and Faculty Member in the Program in Immunology at the University of California, San Francisco.
9/21 152858
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Nicola Cascella, MD
Although there’s currently no cure for schizophrenia, it can be managed with therapy and medication—for some patients, that is. In fact, up to one-half of patients with severe symptoms don’t respond to medication. So how are we to care for this large percentage of patients living with treatment-resistant schizophrenia? That’s the question Dr. Andrew Wilner asks Dr. Nicola Cascella, an Assistant Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine who recently conducted a case study exploring the potential use of deep brain stimulation for patients with treatment-resistant schizophrenia.
Host: Louis Kuritzky, MD
Guest: Karl Doghramji, MD, FAASM, DFAPA
Guest: Julie Flygare, JD
Guest: Phyllis C. Zee, MD, PhD
Excessive sleepiness is a common, highly impactful problem not commonly reported and frequently misdiagnosed by physicians. While prevalence reports of narcolepsy vary, patients often do not seek medical advice for their symptoms or, if they do, they receive inaccurate diagnoses. Because of this, it’s possible that more than 1 in 2000 people are living with narcolepsy. It may even take 10 to 15 years to be diagnosed, during which time these patients are impaired. What signs and symptoms are both clinicians and patients missing?
Tune in to hear a patient, Julie Flygare, JD, recount her bizarre symptoms and receive clinical tips on how to improve your identification of overlooked sleep disorders and narcolepsy. Drs. Zee, Doghramji, and Kuritzky provide their clinical insight and expertise on this serious medical condition that continues to be grossly misdiagnosed, underdiagnosed, and undermanaged. By improving your ability to detect, accurately diagnose, and appropriately manage narcolepsy, you can improve the quality of life and health outcomes for your patients. Find out what subtle signs and red flags you need to be on the lookout for and what exciting therapies are now available for these patients.
Host: Stuart H. Isaacson, MD
Guest: Salima Brillman, MD
Guest: Sean C. Beinart, MD
Join Dr. Stuart Isaacson, a neurologist and movement disorder specialist, as he welcomes fellow neurologist and movement disorder specialist Dr. Salima Brillman and cardiologist Dr. Sean Beinart to discuss neurogenic orthostatic hypotension (nOH) causes, symptomatology, disease burden, and approaches to optimal management involving collaboration between neurology and cardiology specialists.
During their discussion, the following questions will be addressed:
- What is nOH and how is it diagnosed?
- What leads to symptoms of nOH?
- What are some common and less common symptoms of nOH?
- What is the impact of nOH symptoms on the patient and the caregiver?
- How do we approach the management of nOH symptoms?
- How can cardiologists and neurologists collaborate in managing patients with nOH?
For additional reference please review: Cutsforth-Gregory JK, Low PA. Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer. Neurol Ther. 2019 Dec;8(2):307-324.
© 2021 Lundbeck. All rights reserved. UBR-D-100900
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Emily Louise Johnson, MD
According to recent estimates, between 150,000 and 450,000 transgender patients have epilepsy. And as that number is only expected to grow, Assistant Professor of Neurology at Johns Hopkins School of Medicine Dr. Emily Johnson shares key considerations for treating transgender patients with epilepsy.
Guest: Daniel Claassen, MD, MS
Neurogenic orthostatic hypotension (nOH) is a subset of orthostatic hypotension and is prevalent in patients with autonomic dysfunction.1,2 The cardinal symptoms of nOH include dizziness and lightheadedness,3 but frequently could include syncope, cognitive slowing, generalized weakness, coat-hanger (neck and shoulder) headache, fatigue, orthostatic dyspnea, blurred vision, and orthostatic angina.3 According to the Harris Poll conducted among nOH patients and their caregivers, the symptoms of nOH have a negative impact on activities of daily living. The symptoms are often minimized, poorly recognized/evaluated, or inadequately discussed and addressed.4
Patients with nOH may experience symptoms that can make daily tasks a challenge.1,5 The frequency and severity of symptomatic episodes can be unpredictable,6 and it is this unpredictability of events that contributes to a vicious cycle of nOH.1 In this cycle, fear of symptomatic events and falls may lead patients to reduce physical activity.1,5
References:
- Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72.
- Freeman R. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615-624.
- Claassen DO, Adler …
Host: Clete A. Kushida, MD, PhD
Guest: Michael J. Thorpy, MD
While gaps in care remain, the future is bright for patients with narcolepsy. Data from cutting-edge clinical trials were recently presented at 2021 Virtual Sleep, the 35th Annual Meeting of the Associated Professional Sleep Societies, and Drs. Clete Kushida and Michael Thorpy are ready to break it down for you. Join them as they examine the main barriers to timely diagnosis and treatment and then dive into the latest research on currently available and emerging pharmacologic therapies. Tune in to stay up to date on the latest progress and research on the management of patients with narcolepsy.
Guest: David M. Simpson, MD
Guest: Jon T. Gertken, MD
Guest: Stephanie Simon, NP
Find the full Prescribing Information here.
There are multiple ways to incorporate the use of Qutenza, a topical treatment for painful diabetic peripheral neuropathy of the feet, into practice. Tune in to hear Dr. David M. Simpson, Dr. Jon T. Gertken, and Ms. Stephanie Simon share their best practices for administering Qutenza as well as the management of painful diabetic peripheral neuropathy of the feet.
QUTENZA® is a registered trademark of Averitas Pharma, Inc.
© 2021 Averitas Pharma, Inc. All rights reserved.
M-QZA-US-01-21-0065 June 2021
Host: Adnan Subei, DO
Guest: Robert Bermel, MD
Guest: Claire Riley, MD
The emergence of COVID-19 has created an unprecedented medical emergency that both raises new questions and presents updated information each day. This issue is even more pressing for patients with conditions such as multiple sclerosis (MS) who have altered immune systems from both chronic illness and disease modifying therapies (DMTs). While the advent of vaccines has revived hope for a return to normal life, vaccination is not always straightforward for those on or planning to start immunosuppressive therapies such as MS DMT. In this activity, Drs. Claire Riley and Robert Bermel discuss guidance outlined by the National Multiple Sclerosis Society (NMSS) and approaches to implementing these considerations in routine practice.
Host: Jerome Lisk, MD
Guest: Merle Diamond, MD
With migraine as a major global health problem that affects over 10% of the population, approximately 1 billion globally, and about 12% in the US, now more than ever it’s vital that healthcare professionals have a deep understanding of the role of the calcitonin gene-related peptide (CGRP) and its receptor in migraine pathophysiology1,2,3. That’s why Dr. Merle Lea Diamond joins Dr. Jerome Lisk to review that and more.
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet. 2018;392:1789-1858.
- Lipton RB, et al. Neurology. 2007;68:343-349.
- Lassen LH, et al. Cephalalgia. 2002;22:54-61.
USA-334-84583
Guest: Maheen Mausoof Adamson, PhD
Tune in to hear Dr. Maheen Mausoof Adamson, a Clinical Associate Professor of Neurosurgery at Stanford School of Medicine, discuss her study on mental health in women and how we can take a more targeted treatment approach.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Maheen Mausoof Adamson, PhD
Traumatic brain injury, or TBI, manifests differently in men and women. Here to explore these differences is Dr. Maheen Mausoof Adamson, a Clinical Associate Professor of Neurosurgery at Stanford School of Medicine, meets with Dr. Andrew Wilner to discuss traumatic brain injuries in female patients.
Guest: Andy Arwari, MD
With more patients opting for home-based care over long-term, acute, and office-based care, it’s important that we align with our patients on what’s most important to them and how they want to be cared for, especially those who are nearing the end of life.
That’s why VITAS Medical Director, Dr. Andy Arwari, is here to share the purpose of goals-of-care conversations and how an app can aid in determining if an advanced illness patient is eligible for hospice.
Guest: Caroline Hastings, MD
Guest: Raymond Y. Wang, MD
Niemann-Pick disease type C (NPC) is an ultra-rare, inherited, neurodegenerative disease with life-threatening complications. Due to its highly variable onset of neurological symptoms throughout one’s lifespan, recognizing and establishing diagnosis for NPC can be challenging for any clinician.
That’s why Drs. Caroline Hastings and Raymond Y. Wang join Dr. Jennifer Caudle to help address those challenges with a detailed look at this genetic condition, the factors underlying its variable onset and course, and strategies to improve recognition, cross-specialty communications, and time to diagnosis.
Copyright ©2021 Orphazyme A/S. All rights reserved.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nadia N. Laack, MD
As survival for patients with pediatric brain tumors improves, reducing the long-term effects of cancer treatment is increasingly important. Fortunately, proton radiotherapy along with several other advancements are helping us achieve that goal. Here to share the latest treatments for pediatric patients with brain tumors with Dr. Charles Turck is pediatric oncology physician Dr. Nadia Laack.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Acromegaly is a rare disorder caused by excess growth hormone production and is associated with increased morbidity and mortality. Delays in the diagnosis and initiation of therapy or the provision of suboptimal therapy often negatively impact the quality of life of these patients. Join us for this expert interview with Dr. Susan Samson and Dr. Kevin Yuen who offer insights to help you overcome the complex medical challenges often faced when managing patients with acromegaly, including strategies to apply the latest guidelines and the 2020 consensus statement into clinical practice.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Ken Paller, PhD
Lucid dreaming is complex and remains a mystery to many neurologists, but emerging research suggests we may be able to communicate with dreamers in REM sleep. Dr. Andrew Wilner is joined by Dr. Ken Paller, Northwestern University's Director of the Cognitive Neuroscience program and the training program in the Neuroscience of Human Cognition, to discuss his recent research on communicating with lucid dreamers.
Host: Jennifer Caudle, DO
Guest: Michelle Kincaid, MD
Guest: David M. Janicke, MD
What do we need to know about Kcentra®, Prothrombin Complex Concentrate (Human), and its role in coagulation factor replacement for acute deficiencies? Joining Dr. Jennifer Caudle to explore that question and more through the lens of a patient case are emergency medicine specialist Dr. David Janicke and critical care surgeon Dr. Michelle Kincaid.
Please read full Prescribing Information for Kcentra®.
KCT-0052-APR21
Host: Hector O. Chapa, MD, FACOG
Guest: Colin Quinn, MD
Guest: Matthew Wicklund, MD
Dr. Colin Quinn and Dr. Matthew Wicklund discuss the genetic and pathophysiologic underpinnings of limb girdle muscular dystrophy, as well as the use of appropriate diagnostic tests for accurate identification of LGMD.
Host: Jennifer Caudle, DO
Guest: Crystal Proud, MD
Guest: Edward Clinton Smith, MD
Dr. Crystal Proud and Dr. Edward Smith discuss the relationship of DMD genetics and pathophysiology and explain the importance of early diagnosis of Duchenne Muscular Dystrophy and the challenges associated with making this diagnosis.
Host: Michael Greenberg, MD
Guest: Peter B. Crino, MD, PhD
How does tuberous sclerosis impact patients? Dr. Michael Greenberg joins Dr. Peter Crino, the chair of the Department of Neurology at the University of Maryland School of Medicine, to discuss tuberous sclerosis complex, or TSC.
Host: Jerome Lisk, MD
Guest: Ilan Wittstein, MD
How do you mend a broken heart? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, joins Dr. Jerome Lisk to discuss broken heart syndrome and some of its challenges.
Host: Jerome Lisk, MD
Guest: Jerrold Vitek, MD, PhD
Deep brain stimulation, or DBS, is an emerging surgical procedure that may help to manage movement disorders such as Parkinson’s disease. Dr. Jerrold Vitek joins Dr. Jerome Lisk to share what is to be expected when a patient undergoes this type of procedure.
Host: David Weisman, MD
Guest: Adil Javed, MD PhD
How can providers help mitigate the symptoms of a disease a debilitating as multiple sclerosis? Dr. David Weisman examines management strategies for patients with multiple sclerosis with is Dr. Adil Javed, a board-certified neurologist and an Associate Professor of Neurology at the University of Chicago.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Jennifer A. Frontera, MD
Although the impact of COVID-19 can be long-lasting, many have had similar effects, even if they aren’t diagnosed with the disease. Dr. Jennifer Frontera, a neurocritical care specialist and professor of neurology at the NYU Grossman School of Medicine, shares some insight on the neurological symptoms that patients with COVID-19 are facing.
Host: David Weisman, MD
Guest: Mijail D Serruya MD,PhD
Thousands of Americans live with the debilitating aftereffects of stroke, such as arm and communication problems. This makes technological developments like brain-computer interfaces absolutely critical for stroke survivors, but some questions are beginning to arise regarding the ethics of this technology. So in order for us to fully pursue this advancement, it’s important that we address those ethical concerns, as Dr. Mijail Serruya explains.
Host: Patricia K. Coyle, MD
Guest: Jiwon Oh, MD
Treatment goals for patients with multiple sclerosis continue to be refined as more and better disease-modifying drugs emerge from clinical trials and we accrue findings from real-world data. Nonetheless, the decision to match a patient with a particular drug agent has become more complex as we strive to achieve our treat-to-target goals and optimize patient outcomes.
Drs. Coyle and Oh discuss how clinicians can best approach the medical management of patients with multiple sclerosis, both in the short and long term. The goal is to apply best clinical evidence while personalizing a patient’s therapy, thus offering the patient as normal a life as possible.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Ken Tyler, MD
Further complicating the COVID-19 pandemic is the emergence of viral variants. Dr. Ken Tyler from the University of Colorado School of Medicine shares with us what we know so far about the COVID-19 variants that are quickly spreading around the world.
Host: Patricia K. Coyle, MD
Guest: Mitzi Joi Williams, MD
While we are witnessing an impressive expansion in the multiple sclerosis treatment landscape, we cannot lose sight of the fact that a critical component of care is the incorporation of best clinical evidence into the personalized management of each patient.
Join us as Drs. Coyle and Williams discuss how bringing shared decision-making into the management of multiple sclerosis can help us to not only achieve our treat-to-target goals, but also improve patient outcomes and satisfaction.
Guest: Satish R. Raj, MD, MSCI
Neurogenic orthostatic hypotension (nOH) is a subset of orthostatic hypotension and is prevalent in patients with autonomic dysfunction.1,2 In these patients, there is insufficient compensatory peripheral release of norepinephrine, the major neurotransmitter responsible for blood pressure maintenance, upon standing or following postural change.2-4 Due to this norepinephrine deficiency, there is inadequate vasoconstriction to maintain blood pressure or cerebral blood flow.1,5 This may lead to symptoms of nOH which may increase the risk of falls and lead to serious consequences.2,3,6
Here. Dr. Satish Raj, Professor of Cardiac Sciences at the Libin Cardiovascular Institute at the University of Calgary's Cumming School of Medicine and Medical Director of Calgary Autonomic Clinic, discusses the pathogenesis of nOH, as well as the mechanisms behind therapeutic approaches to controlling its effects.
References:
- Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011:21(2) 69-72.
- Low PA. Neurogenic orthostatic hypotension: pathophysiology and diagnosis. Am J Manag Care. 2015;21(suppl 13):s248-s257.
- Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009:119(1):139-146.
- Freeman …
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Drew Weissman, MD, PhD
Dr. Drew Weissman, Professor of Medicine at Penn Medicine joins Dr. Turck to discuss his new COVID-19 vaccine technology and how RNA and mRNA are being used to provoke an immune response in order to combat the COVID-19 pandemic.
Guest: Kevin Strauss, MD
Guest: Chamindra Konersman, MD
Affecting one in every 10,000 births worldwide, spinal muscular atrophy, also known as SMA, can result in the progressive loss of basic muscle function and in its most severe forms, can lead to death or the need for permanent ventilation in 90% of cases by age two. How can we help ensure that patients with this debilitating disease get diagnosed early, and what role does gene therapy play in its treatment? Tune in as Dr. Chamindra Konersman from Rady Children’s Hospital in San Diego discusses that and more with Dr. Kevin Strauss from the Clinic for Special Children in Pennsylvania.
© 2021 Novartis Gene Therapies, Inc. US-ZOL-20-0544 1/2021
Host: Jerome Lisk, MD
Guest: Anthony L. Fine, M.D
Recent advancements in the field of fetal neurology have equipped clinicians to detect neurological diseases before the child is even born. Dr. Jerome Lisk joins Dr. Anthony Fine, a pediatric neurologist and epileptologist at Mayo Clinic in Rochester, to discuss some of these advancements.
Host: Jennifer Caudle, DO
Guest: Wendy J. Sherman, M.D.
Guest: Alfredo Quinones-Hinojosa, M.D.
Brain tumors can be complicated for neurosurgeons to diagnose and treat, but tumors located in eloquent parts of the brain present their own unique set of challenges. How are neurosurgeons managing these complex tumors while protecting their patients’ neurologic function? Dr. Alfredo Quinones-Hinojosa and Dr. Wendy J. Sherman discuss how to diagnoses and carry out brain tumors in eloquent areas.
With state-of-the-art research and laboratory facilities, Mayo Clinic experts are constantly seeking a greater understanding of brain tumors in order to improve patient care. A variety of clinical trials and other studies of tumor biology, neuropathology and epidemiology may be available to for brain tumor treatment at Mayo Clinic.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.
Host: Jennifer Caudle, DO
Guest: Ian F. Parney, MD, PhD
With a variety of novel immunotherapy treatments emerging, the field of oncology care continues to grow and evolve. But when it comes to treating complicated diseases such as brain cancer, is immunotherapy the right option? Dr. Ian F. Parney, a neurosurgeon at Mayo Clinic in Rochester, Minnesota discusses treating brain tumors with immunotherapy and dives into different types of brain tumors, treatment options, and potential side effects.
With state-of-the-art research and laboratory facilities, Mayo Clinic experts are constantly seeking a greater understanding of brain tumors in order to improve patient care. A variety of clinical trials and other studies of tumor biology, neuropathology and epidemiology may be available to for brain tumor treatment at Mayo Clinic.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.
Host: Robert A. Hauser, MD, MBA, FAAN
Guest: Stuart H. Isaacson, MD
Please note: This activity is no longer available for continuing education credit.
This Expert Exchange activity is designed to make clinicians aware of the potential for emerging pharmacotherapies in treating patients with Parkinson’s disease.
You can access the Clinical Compendium for Novel Therapies to Manage OFF Episodes in Patients with Parkinson’s Disease by clicking the link here.
Host: Richard K. Bogan, MD
While positive airway pressure is the standard of care treatment for obstructive sleep apnea (OSA), it may not always be enough to address the excessive daytime sleepiness (EDS) that some patients experience. In fact, in one study, up to 34 percent of patients with OSA still reported EDS (Epworth Sleepiness Score ≥10) despite more than 5 hours of CPAP use a night.
Here, Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc., sheds light on the prevalence of EDS in OSA. Specifically, Dr. Bogan discusses key data that has raised important observations about how commonly EDS may persist even when patients adhere to CPAP therapy.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Host: Jennifer Caudle, DO
Guest: Amit Bar-Or, MD, FRCP, FAAN, FANA
Joining Dr. Jennifer Caudle to discuss the latest research furthering our understanding and treatment of multiple sclerosis is Dr. Amit Bar-Or, Chief of the Multiple Sclerosis Division and Director for the Center of Neuroinflammation and Neurotherapeutics at Penn Medicine. Could these recent findings finally help us solve some of the unanswered questions of multiple sclerosis?
Host: Matt Birnholz, MD
Guest: Emeran Mayer, MD, PhD
There’s no organ in the body that has such close connections with the brain as the gut, which can often result in pain for many of our patients with IBD. Listen in as Dr. Emeran Mayer joins Dr. Matt Birnholz to explain this mind-gut connection, why patients with IBD experience pain, and how providers can manage patients who experience pain when inflammation is and isn't present.
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Maximilian Konig, MD
Guest: Chetan Bettegowda, MD, PhD
For the subset of people who become critically ill from the novel coronavirus, cytokine storms could be to blame. This severe inflammatory disease happens when the immune system goes haywire in response to a novel threat. Rheumatology fellow Dr. Max Konig and neurosurgeon Dr. Chetan Bettegowda talk with Stephanie Desmon about the vital role of cytokine in immune responses, how to identify who might be at risk, and how research is looking into stopping the storms before they start.
Published April 28, 2020
Host: Paul Doghramji, MD
Guest: Maria Escolar, MD, MS
Adrenoleukodystrophy (ALD) is a rare genetic disorder that when left untreated, can have severe and even fatal consequences. Here to review the available treatment options for these patients is Dr. Maria Escolar, the Director of the Program for the Study of Neurodevelopment in Rare Disorders and a Professor of Pediatrics at the University of Pittsburgh School of Medicine.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Paul Orchard, MD
Although it only affects about one in 18,000 people, the impacts of adrenoleukodystrophy cannot be underestimated. That’s why Dr. Paul Orchard joins Mario Nacinovich to talk about this rare—and fatal—genetic disease, why it’s often underdiagnosed and confused with other conditions, and how we can treat it once we’ve reached an accurate diagnosis.
Host: Andrew Wilner, MD, FACP, FAAN
Hysteria is nothing new, but looking at how the spread of misinformation affects this disorder is a new concept. Providing an update to a blog he wrote back in 2012 entitled An Explanation for Mass Hysteria that was also featured in his book Bullets and Brains, Dr. Andrew Wilner dives into the contemporary problem of mass hysteria.
Host: Jennifer Caudle, DO
Guest: Catherine Apicella, MPT, PYT-C, PRPC
With less and less primary care physicians partnering with physical therapists, it’s time we ask: are we doing ourselves—and our patients—a disservice by not taking advantage of this option? To find out, Dr. Jennifer Caudle sits down with physical therapist Catherine Apicella to discuss the often-overlooked benefits of physical therapy and how primary care physicians and physical therapists can work together to benefit their patients.
Host: Patricia K. Coyle, MD
Guest: Clyde E. Markowitz, MD
Please note: This activity is no longer available for continuing education credit.
Multiple sclerosis (MS) is one of the leading causes of disability worldwide. As the treatment armamentarium continues to grow, patient involvement in the development of an effective treatment strategy is becoming increasingly important. In this Clinical ExchangesSMactivity, leading MS specialists discuss issues of diagnosing MS, initiating treatment, and switching therapies, all in the context of practical shared decision-making techniques demonstrated by their own patients.
Host: Andrew Wilner, MD, FACP, FAAN
Even with quick thinking and timely action, the chances of a neurosurgeon being able to do more than taking out the bullet, administering antibiotics, and stopping the bleeding isn’t likely, and surviving a bullet to the brain can unfortunately be just the beginning of a patient’s struggles. Focusing on the title story of his book Bullets and Brains, Dr. Andrew Wilner discusses the serious aftermath congresswoman Gabrielle Giffords experienced while recovering from a headshot.
Host: Matt Birnholz, MD
Guest: Oriana R. Aragón, Ph.D.
While watching a late night show, assistant professor at the University of Clemson Dr. Oriana Aragon witnessed the strong—almost violent—reaction of actress Leslie Bibb toward a cute, little puppy. And we can’t blame Leslie; we've all experienced this overwhelming emotion of adorableness overload, but what does it actually mean? That’s what Dr. Aragon sought to find out.
So are you curious about cute? Cuz we sure are!
Host: Jennifer Caudle, DO
Guest: Catherine Apicella, MPT, PYT-C, PRPC
Frustrating multiple sclerosis (MS) symptoms like urinary frequency and incontinence can be detrimental to a patient’s quality of life, but there are resources available to help. To explore the benefits of pelvic floor physical therapy for MS, Dr. Jennifer Caudle sits down with two special guests: physical therapist Catherine Apicella from CORE 3 Physical Therapy and her patient—and ReachMD’s very own employee—Crystal Gouldey.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: George Paxinos, MD
Generations after Camillo Golgi developed the staining technique enabling scientists to visualize individual neurons as well as their axons and dendrites, some groundbreaking discoveries are again coming to light—like the one neuroscientist Dr. George Paxinos recently uncovered. Dr. Paxinos joins Dr. Andrew Wilner to discuss the endorestiform nucleus, the new anatomical structure in the brain he found using his own special stain for nervous tissue.
Host: Matt Birnholz, MD
Guest: Wes Ely, MD, MPH
After surviving a critical illness, many patients look forward to their lives returning to normal, but unfortunately, that’s not always possible.
To uncover the far-reaching impacts of delirium, Dr. Matt Birnholz is joined by Dr. Wes Ely, Professor of Medicine and Co-Director of the Center for Critical Illness, Brain Dysfunction and Survivorship Center at Vanderbilt University’s School of Medicine which focuses on improving the lives and care of patients in the intensive care unit to ensure both physical and cognitive rehabilitation.
Host: Brian P. McDonough, MD, FAAFP
Guest: David Neagle
Is it possible that our environment and experiences have subconsciously programmed our emotional response to the world around us? Joining Dr. Brian McDonough is David Neagle, author of The Millions Within: Tips to Improve Emotional Intelligence, to offer advice on what impacts our emotional intelligence and the changes we can implement to strengthen our own.
Produced in cooperation with:
Host: Brian P. McDonough, MD, FAAFP
Palliative and hospice care both have very important roles in healthcare, but unfortunately, they are often overlooked as resources.
Dr. Brian McDonough is joined by Chief Medical Officer of Samaritan Healthcare & Hospice Dr. Stephen Goldfine, who offers his perspective on the stigma surrounding these two areas of healthcare and recommendations on how to make the conversation easier for you and your patients.
Host: Maurice Pickard, MD
Guest: Allison Pataki
Five months pregnant, on a flight headed for Hawaii, Allison Pataki's life took a sudden turn when she witnessed her husband, Dave Levy, lose consciousness. After an emergency landing and evaluation, Levy was found to have had suffered a rare stroke.
When he woke the next day, he had amnesia, leaving the young couple holding onto hope for recovery. True to form, Pataki began to write letters to her husband—letters that became the foundation for Beauty in the Broken Places: A Memoir of Love, Faith, and Resilience.
The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly.
A link to the full communication detailing specific information for health care professionals and a list of FDA-approved GBCAs can be found at www.fda.gov/Drugs/DrugSafety
Released 4/25/2018
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Lawrence Robbins, MD
With all headache patients being unique, it's important to come up with an individualized treatment plan. But how do you go about doing that?
Joining Dr. Andrew Wilner is Dr. Lawrence Robbins, Director of the Robbins Headache Clinic in Riverwood, Illinois, to discuss the different approaches you can take when selecting acute, preventive, and behavioral therapies for migraine patients.
Host: Brian P. McDonough, MD, FAAFP
At the age of 35, Jessica Cross was pursuing a rewarding career and raising a family with her loving husband when she was dealt a crippling blow: suffering a stroke that left her paralyzed on the right side of her body and hospitalized for months.
Two years later, still in rehabilitation, Cross began punching at a keyboard to restore function in her arm and hand. Having little interest in typing mindlessly, this daily rehab exercise soon grew into writing what would become the book, Crossed Lines: What Lies Buried Within the Heart.
Host Dr. Brian McDonough sits down with Jessica Cross to talk about her journey through enduring this stroke, her recovery and rehab, and subsequent activism around education and wellness for stroke survivors.
Jessica Cross is an author, speaker, and Executive Director of Strong Cross Foundation.
Host: Shira Johnson, MD
Guest: Bennett Omalu, MD
Chronic Traumatic Encephalopathy (CTE) is a degenerative brain disease found in athletes, military veterans, and others who experience repetitive brain trauma. Pathologist Dr. Bennett Omalu coined the term "CTE" and published the first evidence for this condition after autopsying American football players.
Host Dr. Shira Johnson welcomes Dr. Omalu to share the story of his discovery and the medical, athletic, and public responses that followed.
Host: Jennifer Caudle, DO
Guest: Gordon Baltuch, MD, PhD
Essential Tremor is one of the most common movement disorder, affecting an estimated 3% of the population or approximately 10 million individuals in the United States. A new technology, Focused Ultrasound offers an alternative to traditional surgery that requires no incision or opening of the skull.
Host Dr. Jennifer Caudle is joined by Dr. Gordon Baltuch a professor of Neurosurgery and director of the Penn Center for Functional and Restorative Neurosurgery, to talk about how Focused Ultrasound is an effective treatment for Essential Tremor.
Host: Andrew Wilner, MD, FACP, FAAN
There is still a great deal to learn about the long term effects of blast injuries on military personnel. Emerging evidence suggests that exposure to a blast can produce both overt and subtle neurological consequences in the brain, but much remains unknown.
Host Dr. Andrew Wilner is joined by Dr. Jack Tsao, Director of Traumatic Brain Injury Programs for the US Navy Bureau of Medicine and Surgery, and Professor of Neurology at the University of Tennessee Health Science Center. He is a Captain in the United States Navy, and an expert in detection and prevention of traumatic brain injury in active duty military personnel.
Host: Brian P. McDonough, MD, FAAFP
There is nearly a 20% chance that each of us will suffer a concussion this year. More concerning yet, over 30% of those concussions will lead to a long-term, potentially permanent disability. Many studies have explored how the use of Omega-3 fatty acids may add some measure of resilience within the brain to withstand injury in those at significant risk.
Host Dr. Brian McDonough chats with Dr. Michael Lewis, founder of the nonprofit Brain Health Education and Research Institute about how the utilization of Omega-3 fatty acids may facilitate the concussion healing process and relieve symptoms.
Host: Andrew Wilner, MD, FACP, FAAN
While most people with epilepsy are treated with medications, other modalities such as surgery, diet, and neuromodulation are often necessary. Since the FDA approval of the vagus nerve stimulator in 1997, there has been a growing interest in neuromodulation. A second, more sophisticated device, the responsive neurostimulator, received FDA approval in 2013.
Host Andrew Wilner talks with Dr. Robert Fisher, Professor of Neurology and Director of the Sandford Epilepsy Center at Stanford University about the role of neuromodulation therapy for treatment of epilepsy.
Host: David Weisman, MD
Guest: John Khoury, MD
For the first time, the FDA has approved a direct-to-consumer genetic test from 23andme that will inform patients if they are predisposed to diseases such as Parkinson’s, Alzheimer's, and Celiac Disease among others.
Proponents applaud this decision, saying this will allow for people to know their genetic health risks and be more proactive about their health. Others argue that this information doesn’t tell the whole story since predisposition doesn't reflect someone's ultimate risk or likelihood of developing a disease. What are the benefits and liabilities of consumers' access to genetic testing?
Host Dr. David Weisman, Director of Clinical Trials at Abington Neurological Associates, sits down with Dr. John Khoury, Associate Director at Abington Memorial Hospital Sleep Disorders Center, to debate the merits and pitfalls of direct-to-consumer genetic testing.
Host: Paul Rokuskie
Over the past two decades, the world has seen a dramatic rise of individuals being diagnosed with autism spectrum disorder. For decades scientists and medical professionals have been researching various aspects of this disease to uncover genetic and environmental factors explaining this rapid increase in prevalence; however, discovering definitive clues to causality has proven elusive.
Host Paul Rokuskie talks with Dr. Craig Newschaffer, Professor, Associate Dean for Research, and Director of the A.J. Drexel Autism Institute about the latest research findings into environmental factors affecting autism risk.
Host: Paul Rokuskie
Researchers have been challenged for years by the simultaneous results of numerous studies into brain network connections in individuals with Autism Spectrum Disorder. Some results show strong connections, while others suggest the opposite. New research has helped bring some clarity to this ongoing paradox.
Host Paul Rokuskie is joined by Dr. Benjamin Yerys, a child psychologist in the Center for Autism Research (CAR) at the Children’s Hospital of Philadelphia. They talk about how it’s possible to see conflicting results and, paradoxically, for both to be true.
Host: Paul Rokuskie
Autism Spectrum Disorder affects communication skills as well as emotional & social development. Researchers have been studying the brain for decades to better understand how these developmental differences manifest as autism. Recent studies that measure rapid eye movement (REM) have been showing great promise in elucidating the origins and mechanisms of disease.
Host Paul Rokusie sits down with Dr. John Foxe to talk about his study on rapid eye movement, its implications on disease pathogenesis, and new insights it can bring to future autism research.
Host: Brian P. McDonough, MD, FAAFP
Guest: Allison Willis, MD
More men than women are diagnosed with Parkinson's Disease by almost a 2 to 1 margin. However, women receive supportive surgery less often than men, and their symptoms are more severe on average by the time surgical options are taken.
Host Brian McDonough chats with Dr. Allison Willis, Assistant Professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania, about gender differences in diagnosing and managing Parkinson's Disease.
Host: Brian P. McDonough, MD, FAAFP
Vegetative state is commonly defined as "wakefulness with awareness." Patients with a vegetative state diagnosis will show only reflex behavior, are not able to follow commands and are unable to communicate. This barrier in the inability for patients to communicate can make it difficult for doctors to measure their level of consciousness. In fact, some patients who are believed to be in a completely vegetative state may be more aware of what's going on than people realize.
Host Brian McDonough joins Dr. Adrian Owen, Canada Excellence Research Chair in Cognitive Neuroscience and Imaging at the Brain and Mind Institute at Western University. They talk about how the use of MRI technology is aiding doctors in measuring the level of consciousness in patients under vegetative states.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Elizabeth Donner, MD
Sudden Unexplained Death in Epilepsy (SUDEP) refers to the unexplained death of a seemingly healthy person with epilepsy where no cause of death can be found. What do doctors need to know about this mysterious and devastating phenomenon?
Dr. Elizabeth Donner, Director of the Comprehensive Epilepsy Program and Associate Professor in the Department of Pediatrics at the University of Toronto joins host Dr. Andrew Wilner to talk about the risks and investigated causes of SUDEP.
Host: Brian P. McDonough, MD, FAAFP
Could constant cell phone use be damaging children's brains?
Host Dr. Brian McDonough chats with Daniel Debaun, author of Radiation Nation: The Fallout of Modern Technology," about how electromagnetic frequency (EMF) radiation produced by modern technology such as cell phones, tablets, laptops, Wi-Fi, and smart meters may be emerging as a health threat with many unknown consequences.
Host: Brian P. McDonough, MD, FAAFP
Guest: Annalisa Scimemi
Hemorrhagic strokes account for about 200,000 strokes per year. Of those who survive, about 66 percent suffer some permanent brain damage. Our guest, biophysicist Dr. Annalisa Scimemi, has been studying the receptors in the brain that may contribute to brain damage immediately after hemorrhagic stroke. Alongside host Dr. Brian McDonough, she will discuss how to lessen the effects of brain damage following a stroke.
Host: Kathy King, RDN
Guest: Michael Lewis
A natural nutrition therapy is showing promise for helping patient heal from concussions and traumatic brain injuries. With 3 to 4 ½ million concussions a year from sports, accidents, and military duty, concerns are at an all-time high. Physician and nutrition scientist Dr. Michael Lewis will introduce natural nutrition therapy, a unique way to prevent and treat concussions and brain injuries. Along with our host, Kathy King, he will discuss general nutrition guidelines for improving brain health.
Host: Brian P. McDonough, MD, FAAFP
Guest: Howard Spiva
Wearing a helmet is an overlooked but critical safety precaution, particularly among children. Attorney Howard Spiva knows the lifelong struggle of individuals recovering from traumatic brain injuries, having devoting much of his career to providing helmet safety education for children. Joined by host Brian McDonough, Mr. Spiva discusses important details about helmet safety, the current status of helmet laws, and continuing efforts to reduce traumatic brain injuries nationwide.
In this interview, Lawrence Sherman and Dr. Ralf Gold discusses the study, "Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis," which was led by researchers, Laura Negrotto and Dr. Raul Carrea. They will also discuss the impact of the drugs on clinical biomarkers and MRI, as well as future research on immunologic effects tied to MS.
This interview is supported by an educational grant from Merck KGaA, Darmstadt, Germany.
Host: Matt Birnholz, MD
Guest: Patrick J. Connolly, MD
Back and neck pain is extremely common, with 80-90% of people experiencing some pain within their lifetime. About 90% of cases resolve within six weeks, but for those patients whose pain persists, questions arise as to who should be referred next for further consultation. While patients often see a spine specialist at first, the care journey sometimes leads to a neurosurgeon or orthopaedic spine surgeon. Can this pathway from primary care to neurosurgery or orthopaedic surgery ever be expedited?
Dr. Patrick Connolly, neurosurgeon at Penn Medicine joins host Dr. Matt Birnholz to discuss when primary care physicians should consider referring patients to neurosurgeons for neck and back pain. Dr. Connolly will also discuss the different types of surgical options for patients seeking prolonged back and neck pain relief.
Host: Maurice Pickard, MD
Dr. Maurice Pickards talks with Dr. Edward Shaw about his book Keeping Love Alive as Memories Fade: The 5 Love Languages and the Alzheimer's Journey. Dr. Shaw shares how love can lift a corner of dementia’s dark curtain to cultivate an emotional connection amid memory loss. The book provides focused help for those feeling overwhelmed by the relational toll of Alzheimer’s.
Host: David Weisman, MD
Dr. David Weisman explores a study from Wake Forest School of Medicine that examined the effects of concussions for youth football participants.
This week hosts Mark Masselli and Margaret Flinter speak with renowned neuroscientist Dr. Adam Gazzaley, Director of the Neuroscience Imaging Center and Gazzaley Lab at UC San Francisco. Dr. Gazzaley discusses his closed loop system designed to improve brain function through personalized game design and feedback, which are already undergoing FDA clinical trials for therapeutic interventions for a number of brain disorders including ADHD, aging brain, PTSD and addiction.
Host: Paul Rokuskie
As medical professionals gain better understandings of the etiologies, mechanisms, and progressions of autism spectrum disorder, they are looking for ways to standardize this diagnosis. This creates new needs to change the way autism is conceptualized clinically, from severity scales to behavioral impacts on quality of life.
Host Paul Rokuskie welcomes Dr. Sven Bolte, Professor of Child and Adolescent Psychiatric Science and Director of the Center of Neurodevelopmental Disorders at Karolinska Institute in Stockholm, Sweden. The two discuss the complex process for building new diagnostic criteria for autism spectrum disorder.
Host: Paul Rokuskie
New research is vital toward better understanding the complexities of autism spectrum disorder. Joining host Paul Rokuskie to discuss the latest research projects striving to identify the underlying causes as well as effective treatments for autism is Dr. Robert Schultz, Director of the Center for Autism Research at Children’s Hospital of Philadelphia.
Host: Brian P. McDonough, MD, FAAFP
Health informatics provides a way for knowledge about patients, diseases, therapies and medicines to be more easily shared. Greater access to data can be used to improve healthcare on a larger scale.
Dr. Brian McDonough talks with Dr. Don Liss, Senior Medical Director at Independent Blue Cross about how health informatics is shaping health care.
A protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimer’s disease Rosie Freer, Pietro Sormanni, Giulia Vecchi, Prajwal Ciryam, Christopher M. Dobson, and Michele Vendruscolo
Science Advances 10 Aug 2016: Vol. 2, no. 8, e1600947 DOI: 10.1126/sciadv.1600947
Abstract: In Alzheimer’s disease, aggregates of Aβ and tau in amyloid plaques and neurofibrillary tangles spread progressively across brain tissues following a characteristic pattern, implying a tissue-specific vulnerability to the disease. We report a transcriptional analysis of healthy brains and identify an expression signature that predicts—at ages well before the typical onset—the tissue-specific progression of the disease. We obtain this result by finding a quantitative correlation between the histopathological staging of the disease and the expression patterns of the proteins that coaggregate in amyloid plaques and neurofibrillary tangles, together with those of the protein homeostasis components that regulate Aβ and tau. Because this expression signature is evident in healthy brains, our analysis provides an explanatory link between a tissue-specific environmental risk of protein aggregation and a corresponding vulnerability to Alzheimer’s disease.
Host: Matt Birnholz, MD
Guest: John Y.K. Lee, MD
Guest: Jason G. Newman, MD, FACS
Joining Dr. Matt Birnholz to discuss innovative surgical approaches to cranial base disorders are Doctors John Y. K. Lee and Jason G. Newman. Dr. Lee is Medical Director of the Gamma Knife Center and Associate Professor of Neurosurgery and Otorhinolaryngology-Head and Neck Surgery at the Pennsylvania Hospital. Dr. Newman is Associate Professor of Otorhinolaryngology-Head and Neck Surgery at the Center for Cranial Base Surgery at the University of Pennsylvania.
Host: Matt Birnholz, MD
Guest: Marwan Noel Sabbagh, MD, FAAN, CCRI
Dr. Marwan Sabbagh, Professor of Neurology and Chief of the Memory Disorders Division at Barrow Neurological Institute, describes some of his key priorities for the current and future state of Alzheimer’s care.
Uncover the truth about Alzheimer's in the non-certified educational series, Alzheimer's Disease: Towards Earlier Detection**
Host: Brian P. McDonough, MD, FAAFP
Alzheimer’s Disease is the most common cause of dementia among people aged 65 and older. With the population of older Americans growing, research for new therapies becomes ever more critical. Yet one of the most important factors in advancing research, fundraising, has been hampered by numerous challenges.
Host Dr. Brian McDonough talks with Charles Fushcillo Jr., President and Chief Executive Officer of the Alzheimer’s Foundation of America about the challenges in securing additional funding for Alzheimer’s Research.
[Read the Article]
Patients who might benefit from a heart valve replacement but are too ill for open heart surgery can sometimes undergo a less invasive procedure known as transcatheter aortic valve implantation or "TAVI". About 10% of patients undergoing TAVI can experience small strokes and related brain injury as a complication. A new study found that the use of a cerebral protection device, which captures debris dislodged from blood vessels during the TAVI procedure, reduced the number and volume of brain lesions seen on MRI.
Researchers from the University of Leipzig Heart Center, Germany studied 100 patients with an average age of 80 who underwent TAVI. Half of the patients received the cerebral protection device and the other half did not. Patients underwent brain MRIs before the implantation and again at 2 and at 7 days after the procedure. The results found that using the filter device helped to decrease the number of brain lesions seen in the brain by about half.
[Watch more videos of The JAMA Report]
Host: Jennifer Caudle, DO
Guest: Michael Mullen, MD
Every second counts for stroke patients. During a stroke, two-million brain cells die every minute, making the urgent administration of therapies and treatment vital to ensure a positive outcome.
Host Dr. Jennifer Caudle is joined by Dr. Michael Mullen, Assistant Professor of Neurology at Penn Medicine. They discuss the clinical hallmarks and priority treatment consideration for stroke.
Host: Jennifer Caudle, DO
Guest: Joseph Berger, MD, FACP, FAAN, FANA
Multiple sclerosis is a notoriously difficult disease to diagnose early on. With no singular confirmatory tests yet available, physicians often become reluctant to identify MS in their patients, leading to years of diagnostic and treatment uncertainty. But new innovations are helping doctors establish earlier diagnoses and start more targeted treatments for MS patients.
Dr. Jennifer Caudle welcomes Dr. Joseph Berger, Professor of Neurology at Penn Medicine, to explore some of these innovations advancing MS diagnosis and treatment.
Host: Jennifer Caudle, DO
Guest: Kathryn Davis, MD, MTR
Guest: Timothy Lucas, MD, PhD
According to the epilepsy foundation, epilepsy is the 4th most common neurological problem in the U.S. – only migraine, stroke and Alzheimer’s disease occur more frequently. The average incidence of epilepsy each year in the U. S is estimated at 150,000, or 48 for every 100,000 people.
Host Dr. Jennifer Caudle talks with Doctors Kathryn Davis and Timothy Lucas about advances in treatment for epilepsy at Penn Medicine. Dr. Davis is Assistant Professor of Neurology and Medical Director of the Epilepsy Monitoring Unit and Epilepsy Surgical Program. Dr. Timothy Lucas is Assistant Professor of Neurosurgery, Surgical Director at the Penn Epilepsy Center, and Director of the Penn Center for Laser Neurosurgery.
Host: Brian P. McDonough, MD, FAAFP
Muhammed Ali died on June 3rd, 2016. The cause of death was respiratory complications from septic shock, but his 30-year battle with Parkinson's disease played a major role in his declining health. Did a storied career in boxing contribute to and/or cause the development of this disease?
Dr. Brian McDonough previews the current clinical understandings and medical literature connecting chronic traumatic encephalopathy (CTE) with the development of Parkinson's disease.
Host: Paul Rokuskie
Recent studies have uncovered sex differences in both the neurobiology and phenotypical presentations of autism. These emerging understandings for how autism manifests uniquely in girls vs boys may radically change the way autism spectrum disorder is clinically perceived, improving diagnostic sensitivity and personalizing therapies.
Joining host Paul Rokuskie to discuss this line of research developments in autism spectrum disorder is Dr. Kaustubh Supekar, research scientist in the Department of Psychiatry at Stanford University School of Medicine.
[Read the Article]
Approximately one-third of children who experience a concussion will experience persistent post-concussion symptoms. Researchers have developed a new clinical scoring system that may help predict which patients are at a higher risk for prolonged symptoms.
Canadian researchers evaluated more than 3,000 patients, ages 5 to 18, who presented within 48 hours of an acute head injury. About thirty percent ended up with persistent post-concussion symptoms at 28 days. Researchers identified nine clinical factors that were predictive of post-concussive symptoms. These factors were then used in a twelve point risk score that included items like age, sex, history of migraines or depression, prior history of concussion, and problems with balance.
Although the clinical score was better than a physician's judgement alone, further research is needed before it is fully adopted into clinical practice.
[Watch more videos of The JAMA Report]
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough welcomes John Roman, CEO of Defend Your Head, a sports safety company based in Chester County, PA. Mr. Roman is a former offensive lineman in the NFL with the New York Jets (1976-1983) before launching a 30-year successful career on Wall Street. He joins Primary Care Today to discuss technological advances in helmet design and construction for football players of all ages. His company has recently developed ProTech, a football helmet product using a soft outer-shell technology designed to improve energy and force dissipation and reduction.
[Read the Article]
A new study examined the brains of deceased individuals and found that moderate seafood consumption correlated with lesser Alzheimer disease.
Researchers from Rush University Medical Center in Chicago enrolled older people living in public housing and retirement communities in an ongoing study of memory and aging. Participants had normal memory function when they entered the study and were asked to keep track of their diet using a detailed questionnaire. The participants also agreed to brain donation after they died, providing researchers a total of 286 brains to examine.
They found that participants who reported consuming seafood at least once a week had decreased occurrence of the plaques and tangles associated with Alzheimer disease. Increased seafood consumption was associated with increased brain mercury levels, but the mercury did not appear to have an impact on brain health.
[Watch more videos of The JAMA Report]
[Read the Article]
Glioblastoma is the most devastating form of brain cancer in adults; most patients die within one to two years of diagnosis. A new study examined whether using tumor-treating fields, a type of electromagnetic therapy, combined with maintenance chemotherapy in patients with glioblastoma who had already completed standard chemotherapy and radiation, could increase survival.
Researchers from University Hospital in Zurich, Switzerland are conducting a worldwide trial with 695 glioblastoma patients. One out of three received a standard maintenance course of chemotherapy, while the other two received maintenance therapy plus the tumor treating fields for up to two years.
The current results are for the first 315 patients. Researchers found that use of the tumor-treating fields increased both progression-free survival and overall survival. Overall survival is prolonged by an average of three months in patients getting the tumor-treating fields therapy.
[Watch more videos of The JAMA Report]
Host: Jennifer Caudle, DO
Host Jennifer Caudle, DO welcomes Robert Nagele, PhD, a Rowan University researcher and Professor at the Rowan University School of Osteopathic Medicine. Dr. Nagele and his team are closing in on a new blood test to detect Alzheimer’s, Parkinson’s, MS, cancers and other diseases by searching for the autoantibodies created by the disease processes. The test has initially shown to be remarkably accurate in research trials with a capability to accurately assess the stage of disease. More important, it appears to detect pre-clinical disease, giving physicians an opportunity to intervene with lifestyle changes that delay or defer the onset of symptoms.
This program was recorded live at the American Osteopathic Association's annual medical education conference, OMED2015 in Orlando, FL,
Host: Matt Birnholz, MD
Dr. Matt Birnholz welcomes Dr. Clifton Callaway, Professor and Executive Vice Chairman of the Department of Emergency Medicine at the University of Pittsburg School of Medicine. Dr. Callaway received ACEP's Outstanding Contribution to Research Award for his more than two decades of research dedicated to improving brain resuscitation after cardiac arrest. He joins Dr. Birnholz to discuss a research-guided evolution in resuscitation protocols based on improved physiological understandings of secondary brain injuries, comas, and recoveries.
Host: Maurice Pickard, MD
A traumatic brain injury is a life-changing event, affecting an individual’s lifestyle, ability to work, relationships―even personality. In The Traumatized Brain: a Family Guide to Understanding Mood, Memory, and Behavior after Brain Injury, co-author and neuropsychiatrist Dr. Sandeep Vaishnavi explains how traumatic brain injury, whether mild, moderate, or severe, affects the brain. He describes how emotional symptoms such as depression, anxiety, mania, and apathy can be treated; how behavioral symptoms such as psychosis, aggression, impulsivity, and sleep disturbances can be addressed; and how cognitive functions like attention, memory, executive functioning, and language can be improved.
Host: Kathy King, RDN
Guest: Elizabeth Strickland
Can dietary choices play important health roles for patients with autism spectrum disorders? Addressing this question with host Kathy King is pediatric dietitian Elizabeth Strickland, author of Eating for Autism: The 10-Step Nutrition Plan to Help Treat Your Child's Autism, Asberger's, or ADHD. Ms. Strickland is the founder of ASD Nutrition Seminars & Consulting, a clinical nutrition consulting firm that serves families, professionals, educational systems, and private and government programs. Her work expands nationwide to include providing individualized nutrition therapy to children with autism and related disorders.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough welcomes Dr. Marcy Lake, faculty member of the Kaiser Permanente Family Medicine Residency Program in Portland Oregon and author of a recent article in American Family Physician devoted to disorders of the pituitary gland. Their discussion tours diagnostic considerations toward the workup of pituitary diseases, and emerging treatment paradigms for clinicians at general, endocrinology, and surgical levels of care.
Host: Paul Rokuskie
Andy Bondy, PhD, Co-Founder and President of Pyramid Educational Consultants, Inc. join host Paul Rokuski for an in-depth discussion on the Picture Exchange Communication System (PECS), which allows children with autism who have little or no communication abilities a novel means of communicating non-verbally.
[Read the Article]
Agitation is common in patients with dementia and can contribute to distress for patients and caregivers and an increased risk of institutionalization. Nonpharmacological interventions are recommended as first-line therapy, but many patients fail to respond, and medications are often needed. Currently available medications don't work very well and can have serious side effects. A new study tested a combination of two existing medications, dextromethorphan hydrobromide and quinidine sulfate, to see if this would help control agitation in patients with Alzheimer's dementia.
Researchers from the Cleveland Clinic recruited 220 patients with Alzheimer's dementia and agitation. During a preliminary 10 week trial, participants were randomly assigned to receive either the dextromethorphan- quinidine combination or a placebo.
Results showed that patients receiving the combination medication demonstrated fewer episodes of agitation compared to patients who received the placebo. When agitation did occur, it tended to be less severe. Researchers also found that not only is the combined drug effective, but safe.
[Watch more videos of The JAMA Report]
JAMA Report videos provided pursuant to license. ©2015 American Medical Association, publisher of JAMA® and The JAMA Network® journals.
[Read the Article]
About 42 percent of the general U.S. population has low vitamin D levels. In addition to promoting calcium and bone health, vitamin D may also affect the brain and cognitive function. A new study by JAMA Neurology looked at the association between baseline vitamin D levels and the rate of cognitive decline in a group of ethnically diverse older adults.
A researcher from Rutgers University, along with colleagues from the University of California Davis, studied 382 older adults with an average age of 75. Among the group, 61 percent of participants were women, 41 percent white, about 30 percent were African American and 25 percent were Hispanic. At study enrollment, about 18 percent had dementia, 33 percent had mild cognitive impairment and half were cognitively normal.
Vitamin D levels and cognitive function were measured at baseline. Cognitive function was also followed in 318 of the participants for an average of 5 years.
Researchers found:
- About 60 percent of the group, regardless of their race or ethnicity, was low in vitamin D.
- Vitamin D levels were lower for African American and Hispanics, compared with their white counterparts.
- …
[Read the Article]
Each year, nearly 800,000 Americans experience a stroke, and for survivors, cognitive decline including memory and thinking speed, is a major cause of disability. Many patients experience these declines immediately after a stroke, but a new study examined whether cognitive decline continues several years after the initial stroke.
Researchers from the University of Michigan Medical School, Ann Arbor examined changes in cognitive function in more than 23,000 individuals who were 45 years of age or older. All participants were free of cognitive impairment at the start of the study. Memory and other measures of cognitive function were recorded at the beginning and at regular intervals throughout a six year follow up period. 515 participants experienced a stroke during the study, the rest remained stroke free.
Results found that stroke survivors had a faster rate of cognitive decline after stroke compared with the pre-stroke rate. Stroke was associated with an early decline in cognitive function and also accelerated and persistent cognitive decline over the next six years.
[Watch more videos of The JAMA Report]
JAMA Report videos provided pursuant to license. ©2015 American Medical Association, publisher of JAMA® and …
Host: Paul Rokuskie
Autism Spectrum Disorder has had some profound effects on our global culture over the past few years. As greater understandings of this neurological disorder are communicated by scientists, physicians, advocacy groups, educational professionals and parents, public awareness shifts and societies reshape how autism is ultimately perceived.
Paul Rokuskie welcomes Richard Grinker, PhD, Professor and Chair of Anthropology, and Director of the Institute for Ethnographic Research, at the George Washington University. Their discussion centers on how cultures are affecting the way autism is understood, evaluated, and even diagnosed across the world.
Host: Paul Rokuskie
Social and emotional skills come fairly easily for neurotypical individuals. But for those with a diagnosis of Autism Spectrum Disorder (ASD), these may be some of the most challenging skills to learn. Thankfully there is a lot of experience among educators using techniques to help individuals with ASD become more social. Join host Paul Rokuskie as he welcomes speech/language pathologist Jill Kuzma to discuss therapeutic approaches for social cognitive deficits in children with ASD.
Host: Paul Rokuskie
When Derek Volk's oldest child, Dylan, was two years old, his wife suggested, "Something is not quite right with Dylan." They struggled for the next several years as they were bounced from one diagnostician to another, each offering a unique perspective on Dylan's challenging behaviors. Finally, at eight years old, Dylan was diagnosed with Asperger's Syndrome and the Volk family was able to start making sense of Dylan's differences. In Chasing the Rabbit, authors Derek and Dylan Volk share their respective experiences coping with the challenges of autism in the household and the healthcare system.
Host: Paul Rokuskie
Autism spectrum disorder has been around for centuries, but the modern terminology of how it is defined only started in 1943 by Dr. Leo Kanner of Johns Hopkins Hospital. Since then, the definition of autism has changed many times, refined into today’s current understanding of this mental disorder. But one point of constancy over this time frame has been the advocacy work of mothers and fathers to better understand the disease that impacts their children’s lives, helping educate communities around them in turn to foster greater compassion and awareness.
In this episode of the Autism Spectrum, host Paul Rokuskie speaks with Eustacia Cutler, autism rights advocate and mother of Dr. Temple Grandin, who is often referred to as the first person officially diagnosed with autism in the United States.
Host: John J. Russell, MD
Internationally respected neurologist Frances E. Jensen, M.D. speaks with host John Russell, MD about her book, The Teenage Brain: A Neuroscientist's Survival Guide To Raising Adolescents And Young Adults. This insightful book offers new findings and dispells myths and also provides practical advice for parents and teenagers.
Host: Brian P. McDonough, MD, FAAFP
Dr. McDonough welcomes Dr. Donald Frei, neuroradiologist and Director of Neurointerventional Surgery at Radiology Imaging Associates in Denver, CO. Dr. Frei is working towards establishing state-of-the-art diagnosis and management strategies in treating patients with acute stroke. His procedural specialties include acute catheter directed stroke intervention, angioplasty/stent revascularization of cerebrovascular stenosis and minimally invasive treatment of cerebral aneurysms and arteriovenous malformations.
Host: Paul Rokuskie
Joint attention, one of the defining characteristics of social interactions that becomes impaired in children with autism, is a developmental milestone of great importance to researchers and clinicians alike. With early detection of autism spectrum disorder, children can receive better treatments to gain more exposure and training for critical social processes. But is it possible for early detection of joint attention deficits, even in infancy, to one day serve as diagnostic markers for the disease? Joining host Paul Rokuskie to discuss the state of research and awareness on this developmental milestone for children with autism are Dr. Daniel Messinger, Developmental Psychologist and Professor of Psychology, Pediatrics, and Engineering at the University of Miami, and Devon Gangi, PhD candidate in the Department of Psychology, also at the University of Miami.
Host: Lee Freedman, MD
Cerebrovascular Neurosurgery is the highly specialized care for all aspects of cerebrovascular disease. What are the most common diseases treated by a cerebrovascular neurosurgeon? What are the latest treatment options and advances in this field? Host Dr. Lee Freedman welcomes Dr. Michelle Smith, Assistant Professor of Neurosurgery at the Hospital of the University of Pennsylvania, to discuss these questions and much more.
Host: Paul Rokuskie
Autism is not just a child matter. As the prevelance rates of autism continue to rise, so do the numbers of patients entering adulthood. What are the special challenges faced by these patients, their families, and the clinicians who treat and counsel them both respectively? And how can updated therapeutic approaches help change the life trajectories for adults with autism? Host Paul Rokuskie welcomes Dr. Marsha Mailick, Interim Vice Chancellor for Research and Graduate Education at the University of Wisconsin in Madison, Wisconsin. Her research on autism in adults has brought new awareness and understanding to the special needs of this patient population.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough is joined by Mark Underwood, President of Quincy Bioscience, a biotechnology company focused on the discovery, development and commercialization of novel technologies to support cognitive function and other age-related health challenges such as memory.
Host: Lee Freedman, MD
According to the American Cancer Society, about 10,000 pituitary tumors are diagnosed each year in the United States. What is the state of the art approach to the diagnosis and treatment of these tumors? Dr. Lee Freedman talks to Dr. Sean Grady, Chairman, Department of Neurosurgery Charles Harrison Frazier Professor of Neurosurgery Perelman School of Medicine at the University of Pennsylvania.
Host: Ana Maria Rosario
Senior correspondent Ana Maria Rosario chats with Kate Williams, LMSW, from the Alzheimer's Association's Greater Michigan Chapter. Ms. Williams discusses the prevalence of Alzheimer's disease, the myths and misconceptions, and morbidity and mortality statistics, particularly in women. The risk of Alzheimer's disease in women is 1 in 6, compared to the risk of breast cancer, which is 1 in 12. Physicians and other health care providers are encouraged to visit www.alz.org to find tools and resources for their patients and caregivers. Clinicians can also call the 24/7 helpline at 800.272.3900.
Host: Maurice Pickard, MD
Ha! The Science of When We Laugh and Why wirtten by Scott Weems, PhD examines the internal process of how the brain and the mind operate in interpreting humor. Dr. Weems will also review humor as an exercise for the brain, the psychological and intellectual benefits of humor and what happens physiologically. Dr. Weems' career began as an officer in the U.S. Coast Guard, where he served as communications officer in Kodiak, Alaska. His travels then took him to New Orleans, Boston, Los Angeles, Annapolis, and Little Rock, where he earned graduate degrees in psychology, education, creative writing, and a Ph.D. in cognitive neuroscience from UCLA along the way.
Download and listen today!
Host: Paul Rokuskie
Autism Spectrum Disorder (ASD) is a significant public health issue, affecting over 1% of all American children under the age of 18. One organization, Autism Speaks, is accelerating the care of these individuals and their families to the next level through their Autism Treatment Network, which creates collaborations that bridge multiple discplines across the United States. Joining host Paul Rokuskie to elaborate on this initiative is Dr. Dan Coury, Professor of Pediatrics and Psychiatry at Ohio State University and Medical Director of the Autism Treatment Network.
Host: Michael Greenberg, MD
First described in the 1880s, tuberous sclerosis complex, or TSC, is a genetic disease that affects multiple organs. It can cause tumors in the skin, kidneys, brain, heart, eyes, as well as other organ systems. Most patients who are mildly affected by TSC lead active and productive lives, but it is important to note that TSC is a life-long companion and patients are in need of receiving continuous follow-up care. Host Dr. Michael Greenberg welcomes Steven L. Roberds, PhD, Chief Scientific Officer of the Tuberous Sclerosis Alliance in Silver Spring, Maryland to discuss tuberous sclerosis complex.
Download and listen today!
Host: John J. Russell, MD
In December 2005, the National Football League produced a scientific paper concluding that "professional football players do not sustain frequent repetive blows to the brain on a regular basis." That judgment, implausible even to a casual fan, also contradicted the opinion of a growing cadre of neuroscientists who worked in vain to convince the NFL that it was facing a deadly new scourge: a chronic brain disease that was driving an alarming number of players -- including some of the all-time greats -- to madness. In this conversation with Mark Fainaru-Wada, author of League of Denial, the NFL's apparent efforts to cover up and deny mounting evidence of the connection between football and brain damage over a period of nearly two decades are put into the spotlight.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough is joined by Dr. Beverly Cowart from the Monell Chemical Sciences Center to talk about the neurobiological underpinnings of anosmia (loss of smell), the ways in which this condition presents clinically, and perspectives on how targeted treatments will be developed down the road.
Host: Tim Rush
In such a challenging and time-consuming profession, how can physicians find time to pursue other passions? Host Tim Rush welcomes Dr. Andrew Wilner, neurologist and award-winning author. His latest book, Bullets and Brains, draws on his own experiences as a neurologist to explain, in everyday terms, the dangers that can impact the brain. Dr. Wilner will discuss his career as both physician and author, including his medical missions in the Philippines.
Download and listen in!
Host: Paul Rokuskie
Alzheimer's Disease was first identified more than 100 years ago. Yet despite this century-spanning awareness by medical communities across the globe, the precise physiologic mechanisms triggering the development of this disease are still unknown. Advocacy groups such as the Alzheimer's Association play a critical role in advancing new science and supporting those affected both directly and indirectly by this devastating illness. Joining host Paul Rokuskie to speak on behalf of the Alzheimer's Association's latest advocacy initiatives is Claire Day, Vice President of Constituent Services of the AA's Delaware Valley Chapter.
Host: John J. Russell, MD
In 1998 Andrew Wakefield, a British gastroenterologist with a history of self-promotion, published a paper with a shocking allegation: the measles-mumps-rubella vaccine might cause autism. The media seized hold of the story and, in the process, helped to launch one of the most devastating health scares ever. Yet despite the numerous studies that failed to find any link between childhood vaccines and autism, it has since been popularized by media personalities, and declining vaccination rates have led to outbreaks of deadly illnesses like Hib, measles, and whooping cough. In The Panic Virus: The True Story Behind the Vaccine-Autism Controversy, author Seth Mnookin draws on interviews with parents, public-health advocates, scientists, and anti-vaccine activists to tackle a fundamental question: How do we decide what the truth is?
Host: Paul Rokuskie
It has been over 10 years since the Diagnostic Statistical Manual of Mental Disorders, or DSM, has been updated and released in its fifth edition. There has been much anticipation and controversy over the many changes that have been incorporated, and among the most carefully scrutinized are those pertaining to autism spectrum disorder. Joining host Paul Rokuskie to discuss important DSM-V updates in the diagnosis and classification of autism are Dr. David Kupfer, Chair of the DSM-V Taskforce, and Dr. Catherine Lord of the Neurodevelopmental Disorders Workgroup.
Host: Paul Rokuskie
Applied Behavioral Analysis (ABA) is considered a safe and effective treatment approach for children with Autism Spectrum Disorder, but it is often misconceived by parents and teaching professionals in school settings. Joining host Paul Rokuskie to discuss research behind ABA techniques for increasing positive, useful behaviors and reducing those that may cause harm or interfere with learning is Dr. Gina Green, Executive Director at the Association of Professional Behavioral Analysis.
Host: Paul Rokuskie
Host Paul Rokuskie is joined by Drs. Declan Murphy and Will Spooren. Dr. Murphy is Professor of Psychiatry and Brain Maturation at Kings College, London, and Dr. Spooren is Group Leader of Behavioral Pharmacology at Roche Pharmaceuticals. Their topic for discussion is the large academic and industrial consortium known as European Autism Interventions, or EU-AIMS, which serves as a collaborative network bridging experts in autism across the spectrum of pharmacologic research and development.
Host: Paul Rokuskie
Autism Spectrum Disorder is one of the greatest medical and social challenges facing not only the United States, but the entire world. As the medical community focuses resources on finding the causal factors for autism and delivering viable treatment options for patients, key specialists in translational neurobiology research are leading the charge. Dr. Robert Ring, Vice President and Head of Translational Research for Autism Speaks, the world's leading autism science and advocacy organization, speaks with host Paul Rokuskie about current advances in understanding, diagnosis, and treatment for this disorder.
Host: Paul Rokuskie
Host Paul Rokuskie is joined by Mercedes Ignasiak and Vanessa Vega, both parents of children with autism. Their conversation centers on the impact of this disease on entire families, how parents manage autism at home, and their roles as key contributors to the healthcare team.
Host: Brian P. McDonough, MD, FAAFP
Host Dr. Brian McDonough is joined by Dr. Karl Doghramji, Professor of Psychiatry and Medical Director of the Jefferson Sleep Disorders Center at Jefferson Medical College in Philadelphia, PA. Dr. Doghramji speaks on the latest trends and updates from his field of expertise, sleep medicine.
Host: Matt Birnholz, MD
Traumatic brain injury, or TBI, is a serious public health problem that affects approximately 1.7 million Americans every year. Of all injury deaths in our country, one in three cases are TBI-related, and an estimated 5.3 million Americans are living with a TBI-related disability. Beyond the potential for impairment to the cognitive, sensory, and motor functions in an individual, the economic burden of TBI is in excess of $76.5 billion. While significant advances in early treatment and prevention policies such as seat belt and motorcycle helmet laws have proven successful in reducing severe cases of TBI, many public health challenges remain. In addition to the economic impact of TBI, there is need for better surveillance, data, and coordination among the medical, public health and community sectors on both the civilian and military sides of the aisle.
This session of CDC′s Public Health Grand Rounds further addressed these challenges and explored promising policies, guidelines, and interventions such as progesterone treatments to further reduce the severity and number of cases of traumatic brain injury in the U.S.
This is Part 1 of a lecture in three parts.
Part 2 >>
Part 3 >>
To view the complete video recording of …
Host: Anthony Alessi, MD
Guest: Lisa Shulman
Would it be better for Parkinson's patients to meet with their doctor in a group setting? Group visits are among the the novel approaches being studied for Parkinson's patients. Dr. Lisa Shulman, professor of neurology and co-director of the Maryland Parkinson's Disease and Movement Disorders Center in Baltimore, joins host Dr. Anthony Alessi to discuss who might benefit from group visits, how it compares to traditional care, and the practical billing issues involved. They also discuss new research on treadmill walking in the treatment of patients with Parkinson's disease.
Host: Lee Freedman, MD
Guest: Neil Malhotra, MD
How much do quality improvement efforts improve quality of life for neurosurgical patients? Host Dr. Lee Freedman talks to Dr. Neil Malhotra, assistant professor of neurosurgery at the University of Pennsylvania and the Penn Neurological Institute of the Pennsylvania Hospital, about new efforts to improve outcomes in this area. They also look at latest treatments and techniques in Dr. Malhotra's area of surgical expertise, the treatment of degenerative disc disease.
Guest: Bruce Aylward, MD, MPH
Host: Jennifer Shu, MD, FAAP
This year's meeting was held from April 9 to 16 in Honolulu, attracting approximately 10,000 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in neurology, and highlighting recent advances in neurological disorders.
Host: Lee Freedman, MD
Guest: John Y.K. Lee, MD
3-D technology is making its way from the movies, into the operating room. How is this technology enhancing brain surgeries? Dr. John Y.K. Lee, medical director of the Penn Gamma Knife Center and assistant professor of neurosurgery at Penn Medicine, describes the advantages of using 3-D technology for removing various types of ventral skull-based tumors, and says the stereoscopic views provided by a 3-D endoscope help neurosurgeons preserve critical areas of the brain. Will 3-D endoscopes replace their 2-D predecessors? Dr. Lee Freedman hosts.
Produced in Cooperation with
Host: Matt Birnholz, MD
For people who carry genetic predispositions toward Alzheimer's disease, little is currently known about predicting the onset, course, and severity of disease at the individual level. However, because cogntitive degenerative diseases most often follow a gradual course of symptom progression later in life, medical professionals must be aware of the distinct, discoverable changes that occur at the "preclinical" stage, i.e prior to the symptomatic onset of memory loss.
In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about Alzheimer's Disease from a unique perspective of the preclinical stage. From classical signs on physicial exam to emerging biomolecular lab tests and novel imaging modalities, the pathophysiologic changes underlying Alzheimer's disease are explored in depth.
Presenting this session of Grand Rounds is Dr. Richard Caselli, behavioral neurologist and professor of neurology at the Mayo Clnic in Scottsdale, Arizona.
This is Part 1 of a lecture in three parts.
Part 2 >>
Part 3 >>
To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.
Host: Eric Tangalos, MD
Guest: Tena Alonzo, MA
How can creating a more positive emotional experience for patients with dementia or Alzheimer's diminish behavior issues and improve quality of life? Tena Alonzo, director of research and co-director of the Palliative Care for Advanced Dementia program at Beatitudes Campus in Phoenix, discusses a common-sense approach to creating a comforting environment for those with dementia and Alzheimer's, which focuses on meeting each patient's unique needs. What simple steps can long-term care facilities and caregivers take to enhance the lives of patients with cognitive disorders? Dr. Eric Tangalos hosts.
Host: Matt Birnholz, MD
Recognizing the respiratory manifestations of neuromuscular disease in children is a critical first step toward protecting their survival and improving their quality of life. In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about the art of assessing respiratory problems in these children, and the treatment options available for optimizing long-term management.
Presenting this session of Grand Rounds is Dr. Cori Daines, pediatric pulmonologist and associate professor of pediatrics at the University of Arizona College of Medicine. Dr. Daines is director of the pediatric bronchoscopy program, and co-director of the Tuscon Cystic Fibrosis Center.
This is Part 1 of a lecture in three parts.
Part 2 >>
Part 3 >>
To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.
Host: Anthony Alessi, MD
Guest: Carl Ansevin, MD
For the 12 million Americans who suffer from restless leg syndrome (RLS), the disease can often be misdiagnosed and misunderstood. Doctors as well as their patients are now more familiar with RLS due to the intense marketing of drugs used to treat restless legs syndrome. Host Dr. Anthony Alessi talks with Dr. Carl Ansevin, an adjunct faculty member in the department of biomedical sciences at Kent State University and sleep specialist at the Ohio Neurologic Institute in Boardman, Ohio, about how to properly diagnose and treat restless leg syndrome and which patients are more at risk of developing the disease.
Host: Anthony Alessi, MD
Guest: Don Iverson, MD
Nationwide there are an estimated several hundred thousand licensed drivers with Alzheimer's disease. A new study shows that more than half can still pass a road test, leaving physicians to help patients and caregivers decide when it's time to stop driving. Dr. Donald Iverson, lead author of the American Academy of Neurology's most recent guidelines on driving and dementia, joins host Dr. Anthony Alessi to discuss what tests are available to help make this decision, and how to approach the delicate discussion of this loss of independence with Alzheimer's patients.
Host: Eric Tangalos, MD
Guest: James E. Galvin, MD, MPH
Early detection of various conditions can help physicians better manage and treat their patients, and Alzheimer's is no exception. What early screening tests of cognitive impairment or dementia should be administered by primary care providers help detect when the disease process is beginning? Dr. James Galvin, professor in the departments of neurology and psychiatry at New York University Langone Medical Center in New York City, joins host Dr. Eric Tangalos to discuss the correlation between higher scores on cognitive impairment screening tests (such as the AD8 dementia screening test) and the presence of biomarkers for Alzheimer's. How effective is second stage confirmation of Alzheimer's with the use of biomarkers, and what role will biomarkers play in development of new therapies for this condition?
Host: Eric Tangalos, MD
Guest: Herbert Sier, MD, CMD
What are some of the unique issues related to patients with Parkinson's in long-term care, and how can all long-term care team members assess and manage the condition? Dr. Herbert Sier, associate chief of geriatrics and assistant professor of medicine at Northwestern University Feinberg School of Medicine, and vice president of medical affairs at the nonprofit community organization, CJE Senior Life, in Chicago, Illinois, joins host Dr. Eric Tangalos to discuss ways physicians can preserve and improve mobility for Parkinson's patients, while providing for appropriate psychological care as well. Hosted by Dr. Eric Tangalos.
Guest: William Thies, PhD
Host: Bruce Japsen
Some 5 million Americans have Alzheimer's disease, with more cases sure to develop as the baby boomer generation ages. New potential discoveries are on the horizon. But, as Dr. William Thies, chief medical and scientific officer for the national office of the Alzheimer's Association, tells host Bruce Japsen, significant challenges and obstacles also lie ahead for these potential ground-breaking discoveries.
Host: Mark Chyna, MD
Tune in to coverage of research highlights from the AAN's annual 2010 meeting in Toronto.
Guest: Jaime Toro, MD
Host: Martin Samuels, MD
Are there lessons to be learned about the U.S. healthcare system — both in terms of patient care and medical education — from physicians practicing abroad? Joining host Dr. Martin Samuels to discuss this and other topics is noted neurologist and educator Dr. Jaime Toro.
Host: Martin Samuels, MD
Host Dr. Martin A. Samuels, neurologist-in-chief and chairman of the department of neurology at Brigham and Women's Hospital, and professor of neurology at Harvard Medical School, answers your questions about promising therapies for ALS, the role of exercise for Parkinson's disease patients, sleep apnea, and more. If you are a healthcare professional and have a question you want to ask the neurologist, email it to inspired@reachmd.com.
Host: Anthony Alessi, MD
Guest: Mill Etienne, MD, MPH, CPH
Host Dr. Anthony Alessi interviews neurologist Lt. Cmdr. Mill Etienne, MD, at St. Damien's Pediatric Hospital in Port-au-Prince, Hati. Dr. Etienne is a Hatian-American physician in the United States military, stationed on the USNS Comfort. They discuss Dr. Etienne's work providing medical care, in addition to translation services and cultural sensitivity training for the staff on board the Comfort, and lessons he has brought from the American Academy of Neurology's Palatucci Advocacy Leadership Forum (which trains selected members to be effective advocates for patients at the local, state, and national levels.) At the end of the interview, find out how you can still help in Haiti.
Host: Steven Edelman, MD
Guest: Irwin Goldstein, MD
The vascular, neurologic, hormonal and psychological issues associated with the diabetes and metabolic syndromes are commonly the cause of sexual problems. What benefit does a multidisciplinary approach to sexual medical issues bring to people living with diabetes? Join host Dr. Steven Edelman and his guest, director of San Diego Sexual Medicine at Alvarado Hospital in Southern California, Dr. Irwin Goldstein, as they discuss both male and female sexual dysfunction, treatments and a multidisciplinary approach to sexual medical issues.
Host: Anthony Alessi, MD
Guest: Ralph Sacco, MD
Dr. Ralph Sacco, neurologist-in-chief at Jackson Memorial Hospital and the Miller Professor of Neurology, Epidemiology and Human Genetics at the Univeristy of Miami, joins host Dr. Anthony Alessi to discuss the FDA-approved treatment approaches for acute ischemic stroke, and what proportion of stokes each year are now treated with IV rTPA. Additionally, Dr. Sacco reviews the newly designated primary stroke centers throughout the United States, and how these have helped expand the treatement of stroke and organized healthcare professionals to provide the right treatment program for their patients in hospitals.
Guest: Sir Roger Bannister, MD
Host: Martin Samuels, MD
Does overcoming defeat and reversal in sports lead to success in career? Joining host Dr. Martin Samuels is Sir Roger Bannister, who as a medical student in May, 1954, shattered a barrier in athletics that many believe stands as one of the greatest athletic accomplishments of the 20th century. But success did not come easily to Sir Roger. He and Dr. Samuels discuss breaking the record, and then choosing to retire as a running and begin his "real" career as a world class neurologist.
Host: Martin Samuels, MD
Host Dr. Martin A. Samuels, neurologist-in-chief and chairman of the department of neurology at Brigham and Women's Hospital, and professor of neurology at Harvard Medical School, answers your questions about promising therapies for ALS, the role of exercise for Parkinson's disease patients, sleep apnea, and more. If you are a healthcare professional and have a question you want to ask the neurologist, email it to inspired@reachmd.com.
Host: Anthony Alessi, MD
Guest: Bruce Miller, MD
Alzheimer’s disease is the sixth leading cause of death in the United States. What advancements and treatments are available to help our patients through both the diagnosis, and prevent the onset? Dr. Bruce Miller, the A.W. and Mary Margaret Clausen Distinguished Professor of Neurology and Psychiatry and director of the Memory and Aging Center at the University of California, San Francisco, joins Dr. Anthony Alessi to discuss the state of Alzheimer's disease today, including how to help our patients who are just presenting with complaints of forgetfulness and fear of Alzheimer’s.
Host: Anthony Alessi, MD
Guest: Lily Jung, MD
What's new in the diagnosis and treatment of multiple sclerosis? Dr. Lily Jung, medical director of the Neurology Clinic and chief of neurology at Swedish Hospital Medical Center in Seattle, joins host Dr. Anthony Alessi to discuss the current state and future technologies available for the treatment of patients with MS.
Listen to highlights of research presented at the Alzheimer's Association 2009 International Conference on Alzheimer's disease. This meeting was held July 11th through the 16th, in Vienna, Austria. Over 3,800 people came from around the world to attend over 100 plenary and symposium sessions.
Guest: Joseph Maroon, MD
Host: Bruce Japsen
It takes more than orthopedic specialists and personal trainers to keep professional athletes ready to play their best. Today's team physicians are noted researchers and leading specialists who perform alongside Super Bowl champions. Dr. Joseph Maroon, neurosurgeon at the University of Pittsburgh School of Medicine and the neurosurgeon for the Pittsburgh Steelers, tells host Bruce Japsen about what he's learned from 20 years of caring for professional athletes and in the course of his own research along the way.
Guest: Jeff Bazarian, MD
Host: Shira Johnson, MD
Brain injuries have come to the forefront since actress Natasha Richardson died following a skiing accident. Concussions are one of the most common injuries seen in emergency rooms across the country, but hundreds of thousands of people hit their heads every year and are never seen by a doctor. Dr. Jeff Bazarian, an associate professor of emergency medicine, neurology and neurosurgery at the University of Rochester in Rochester, New York, joins host Dr. Shira Johnson to discuss a blood test that could diagnose a brain injury without a CT scan.
Guest: Donald O'Rourke, MD
Host: Lee Freedman, MD
Awake craniotomy offers many advantages to brain tumor surgery, since it allows neurosurgeons to maximize surgical resection, while minimizing neurologic risks. Is this procedure well tolerated by most patients? What role does MRI mapping play in awake craniotomy? Dr. Donald O'Rourke, associate professor of neurosurgery at the University of Pennsylvania Neurological Institute and the Abramson Cancer Center at Penn Medicine, discusses the exciting advances being made with awake craniotomy with host Dr. Lee Freedman.
Produced in Cooperation with
Guest: John Whapham, MD, MS
Host: Mark Nolan Hill, MD
Somewhere in between the fields of neurology and neurosurgery, we find physicians using less invasive techniques to perform procedures that could be classified as endovascular neurosurgery, or interventional neuroradiology, or more plainly, as neurology practiced through catheters. Dr. John Whapham, a neurointerventionalist and an assistant professor in the departments of neurology and neurological surgery at the Loyola University Chicago Stritch School of Medicine, explains how this area of practice has evolved in recent years, and previews what's in store for the future of this discipline, blending expertise across multiple specialties. Dr. Mark Nolan Hill hosts.
Host: Martin Samuels, MD
Host Dr. Martin A. Samuels, neurologist-in-chief and chairman of the department of neurology at Brigham and Women's Hospital, and professor of neurology at Harvard Medical School, answers listeners' emailed questions.
Tune in for new research and clinical findings presented at the American Academy of Neurology's 61st annual meeting, which took place April 25th through May 2nd, in Seattle.
Guest: Randy Blakely, PhD
Host: Vatsal Thakkar, MD
Dopamine is an important neurotransmitter in the cortex, essential to movement and activity control, as well as attention and executive function, tying this transporter to ADHD. How are scientists finding the genetic markers that may be transmitted to those with ADHD, and how does this help scientists understand more about the disorder? Dr. Randy Blakely, director of the Center for Molecular Neuroscience at the Silvio O. Conte Center for Neuroscience Research and the Alan D. Bass Professor of Pharmacology and Psychiatry at the Vanderbilt University School of Medicine, describes a genetic mutation that causes the dopamine transporter to run backwards, and how this discovery is helping scientists understand the mechanisms of ADHD. Dr. Vatsal Thakkar hosts.
Guest: Richard Rubin, MD
Host: Vatsal Thakkar, MD
Although stimulant medications are often used to treat ADHD patients, there are patients for whom non-stimulants might also be a viable option. What are the advantages to each type of medication? Dr. Richard Rubin, clinical associate professor at the University of Vermont College of Medicine and adjunct associate professor of child psychiatry at Dartmouth Medical College, joins host Dr. Vatsal Thakkar to discuss medication options for treating patients with ADHD.
Guest: Gene Barnett, MD
Host: Mark Nolan Hill, MD
Even after surgery, radiation and chemotherapy, many brain tumors appear frustratingly unresponsive to treatment. Part of the trouble is that malignancies can be very difficult to reach with conventional therapy. A novel fiber-optic laser that employs heat therapy may provide unprecedented access to previously unresectable tumors, as well as added ability to focus heat directly on the tumor cells. Dr. Gene Barnett, director of the Cleveland Clinic's Brain Tumor and Neuro-Oncology Center, explores what the future may hold for this intriguing experimental technique with host Dr. Mark Nolan Hill.
Guest: Thomas Swift, MD
Host: Martin Samuels, MD
Is there a way that neurologists view the world that is different from other MDs? Are there lessons for all doctors based on this perspective? Host Dr. Martin Samuels talks with Dr. Thomas R. Swift, past-president of the American Academy of Neurology, about these and other topics.
Guest: Ralph Sacco, MD
Host: Shira Johnson, MD
Over 700,000 Americans have a new or recurrent stroke each year. Dr Ralph Sacco, professor and chairman of neurology at the University of Miami's Miller School of Medicine, discusses the leading research on treatment in the 'golden hour' after a stroke occurs. He reviews why thrombolytics have led the way after a dry infarct, but why your patients may need additional care only available in a comprehensive stroke center. As chief of neurology at Jackson Memorial Hospital in Miami and a leading researcher, Dr. Sacco joins host Dr Shira Johnson to talk about the state of the art in care after a CVA.
Guest: Keith Black, MD
Host: Mark Nolan Hill, MD
Despite our best efforts at surgery and chemotherapy for patients with glioblastoma, survival time is often far too limited. One novel weapon in our arsenal could be a vaccine that bolsters the immune system in the body's fight against these tumors. As we move forward with research toward a vaccine, what are the keys to boosting its efficacy? How much additional time could a vaccine buy for our glioblastoma patients? Host Dr. Mark Nolan Hill probes these questions and more with Dr. Keith Black, professor of neurosurgery and chair of the department of neurosurgery, and director of the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center in Los Angeles. Dr. Black also describes the fascinating process by which the research team collects tissue from each patient, which is subsequently applied toward the formation of a vaccine customized for the individual's condition.
Guest: Douglas Nordli, MD
Host: Jennifer Shu, MD, FAAP
The ketogenic diet has been used as a therapy for refractory epilepsy in children since the 1920's. It was only recently, however, that a randomized, controlled study confirmed it to be effective in reducing seizures. Is there a role for the ketogenic diet as first-line therapy for epilepsy? Which patients stand to benefit the most from this diet, and what are some of its potential adverse effects? Dr. Douglas Nordli, associate professor of neurology and pediatrics at Northwestern University's Feinberg School of Medicine, and the Lorna S. and James P. Langdon Chair of Pediatric Epilepsy, offers details on this trial and explores mechanisms through which we may generate more timely results in our research for patients with epilepsy. Dr. Jennifer Shu hosts.
Guest: James McGaugh, PhD
Host: Michael Greenberg, MD
How can beta-blockers influence the formation of memories? Can beta-blockers erase memories entirely, or do these medications only affect the way or degree to which a memory is imprinted? Dr. James McGaugh, founding director of the Center for Neurobiology and Memory at the University of California, Irvine, explains the way beta-blockers can be used to treat post-traumatic stress disorder. What are the ethical concerns about pharmacologically manipulating our anxieties or stresses? Dr. Michael Greenberg hosts.
Guest: Matthew A. Menza, MD
Host: Larry Kaskel, MD
Could tricyclic antidepressants be more effective at treating depression in patients with Parkinson's disease? They have been used since the 1950s for treatment of depression, but in recent years, selective serotonin reuptake inhibitors (SSRIs) have become the predominant form of therapy. New research is suggesting that SSRIs may not be the best antidepressant option for our patients with Parkinson's. The lead author of this research, Dr. Matthew Menza, professor of psychiatry and neurology, and interim chair of psychiatry at the Robert Wood Johnson Medical School, speaks with host Dr. Larry Kaskel about the potential implications of his study on how we care for our Parkinson's patients who are also suffering from depression. Dr. Menza also explores a few other relevant issues: the reticence, among many of those with Parkinson's, to speak with their physician about depression, and the concurrent reluctance, among many in the medical community, to recognize and treat their patients' vulnerability to depression.
Guest: Matthew B. Stern, MD
Host: Jennifer Shu, MD, FAAP
Medication and physical therapy have been mainstay treatments for controlling neurologic symptoms associated with Parkinson's disease. One strategy for mitigating the characteristic tremors, rigidity and slow movement has focused on deep brain stimulation (DBS). What are the risks and benefits of this surgical intervention, when is it indicated, and how does it compare with medical treatment for Parkinson's? Host Dr. Jennifer Shu welcomes Dr. Matthew Stern, the Parker Family Professor of Neurology and director of the Parkinson's Disease and Movement Disorders Center at the University of Pennsylvania School of Medicine, to explore DBS and its indication for your patients with Parkinson's disease. Dr. Stern also offers his view on the question of whether DBS could eventually be considered for treatment much earlier in the disease's progression, or potentially as a first-line therapy for patients with Parkinson's.
Guest: Peter Goadsby, MD, PhD
Host: Mary Leuchars, MD
Occipital Nerve Stimulation has recently emerged as a novel form of therapy for patients with intractable cluster headaches. Could it be the hallmark of a new era in stimulation therapies for primary headache syndromes? Joining host Dr. Mary Leuchars to share insights on this subject is neurologist Dr. Peter Goadsby, director of UCSF's Headache Center and a world expert on trigeminal autonomic cephalgias, or TACs.
Guest: Murray Raskind, MD
Host: Lee Freedman, MD
The sleep disruptions and irritability that often affect patients with post-traumatic stress disorder (PTSD) can be challenging to treat with traditional psychotherapy or pharmacologic treatments. Host Dr. Lee Freedman welcomes Dr. Murray Raskind, professor and vice-chairman in the department of psychiatry and behavioral sciences at the University of Washington School of Medicine, to discuss the benefits of using prazosin to treat PTSD symptoms.
Guest: Henry T. Greely, JD
Host: Cathleen Margolin, PhD
How might society best respond to the growing demand for cognitive-enhancing drugs by healthy individuals? That's the overriding question posed in a recent article published in Nature, written by a team of authors led by Henry Greely, professor of law and director of the Center for Law and the Biosciences at Stanford University. Mr. Greely joins host Dr. Cathleen Margolin to evaluate the appeal and the risks of drug-propelled cognitive enhancement, from safety considerations for healthy individuals using such medications, to the fairness of comparing the achievements of those who use versus those who do not, and the potential for coercion by superiors aiming, in theory, for enhanced performance from subordinates. One other question they will consider: is there a moral difference between cognitive enhancement through pharmaceuticals versus enhancement through sleep or nutritionally beneficial food products?
Host: Michael Greenberg, MD
Guest: Anne Louise Oaklander, MD, PhD
An HIV-positive patient developed shingles. After the shingles healed, this patient began experiencing a very severe unremitting itch, which caused her to scratch through her own skull while sleeping one night. How is this possible, and what are the mechanics of itch that would allow a patient to feel no pain from scratching? Dr. Anne Louise Oaklander, associate professor of neurology at Harvard Medical School, reveals the pathophysiology of neurological itch. Is itch really just low-level firing of pain neurons, or is itch entirely distinct? Dr. Michael Greenberg hosts.
Guest: Aviva Abosch, MD, PhD
Host: Leslie P. Lundt, MD
Increasingly, depression is viewed a systems-level disorder. For patients who are refractory to the all traditional therapies, surgery on the brain may be answer. What are the benefits, and how is psychosurgery different than it was 50 years ago? Dr. Leslie Lundt is joined by Dr. Aviva Abosch, director of the Epilepsy and Functional Neurosurgery Program, and assistant professor in the department of neurosurgery, at the University of Minnesota Medical School in Minneapolis.
Guest: Patrick Frias, MD
Host: Jennifer Shu, MD, FAAP
Although sudden death in the pediatric population is rare, there has been a great deal of discussion recently over the possibility of an increase in risk of sudden cardiac death among individuals taking stimulant medication for attention-deficit hyperactivity disorder (ADHD). Dr. Patrick Frias, a pediatric cardiologist and electrophysiologist at Sibley Heart Center Cardiology in Atlanta and associate professor of pediatrics at Emory University School of Medicine, explores this discussion with host Dr. Jennifer Shu. How can we best evaluate our patients' risk for sudden death before initiating medical treatment for ADHD, and how often should we monitor their cardiovascular status?
Guest: Hyunmi Choi, MD
Host: Larry Kaskel, MD
Is brain surgery better than medicine for temporal lobe epilepsy? Host Dr. Larry Kaskel talks with Dr. Hyunmi Choi, assistant professor of clinical neurology at Columbia University Medical Center in the Comprehensive Epilepsy Center, about her research into the benefits of brain surgery over continued medication management.
Guest: Jose Biller, MD
Host: Mark Nolan Hill, MD
Though innovations in surgical technology and anesthetic techniques have greatly improved the outlook following cardiac surgery, we must remain attentive to the possibility of post-operative complications. One area of concern includes adverse neurologic outcomes. Dr. Jose Biller, professor of neurology and neurological surgery at the Loyola University Chicago Stritch School of Medicine and chair of neurology at Loyola University Health System, talks with host Dr. Mark Nolan Hill about the key considerations for evaluating cognitive changes following a cardiac procedure. Excluding the most evident post-operative neurologic sequelae, how should we proceed in determining that there is a real problem?
Guest: Steven Dubovsky, MD
Host: Lee Freedman, MD
How have neurosurgical procedures for psychiatric conditions advanced since the development of the lobotomy? Which types of neurosurgical procedures are best for treating depression or obsessive-compulsive disorder? Dr. Steven Dubovsky, professor and chair of the department of psychiatry at the State University New York at Buffalo, explains lesioning surgeries, vegus nerve stimulation and deep brain stimulation for treating depression. Dr. Lee Freedman hosts. Can these procedures cure patients of their psychiatric conditions?
Guest: John A. Cairns, MD
Host: Doug Weaver, MD
Long-term anticoagulation is often viewed as inconvenient and somewhat risky, even for patients with atrial fibrillation who are at elevated risk for stroke. Are these factors overshadowing the evidence that demonstrates the effectiveness of anticoagulant therapy in preventing stroke? Dr. John Cairns, professor of medicine in the division of cardiology at the University of British Columbia in Canada, talks with host Dr. Doug Weaver about stroke prevention for patients with atrial fibrillation. Is it safe to stop anticoagulant therapy in this population, and if so, when should this decision be considered?
Guest: Matthew A. Menza, MD
Host: Leslie P. Lundt, MD
Depression is present in as many as half of the one million people with Parkinson's disease in the United States. What evidence-based treatments should we be using? Host Dr. Leslie Lundt welcomes Dr. Matthew Menza, professor of psychiatry and neurology at Robert Wood Johnson Medical School, to talk about his work on diagnosing and treating depression in Parkinson's disease patients.
Guest: Berish Rubin, PhD
Host: Bruce Bloom, DDS, JD
In only three months' time, researchers Dr. Berish Rubin and Dr. Sylvia Anderson and their team uncovered the genetic cause of familial dysautonomia (FD). Dr. Rubin, professor in the department of biological sciences at Fordham University, joins host Dr. Bruce Bloom to share his story and the research that led them to identify the gene mutation responsible for FD, a variation most often found in the Ashkenazi Jewish population. They also discuss symptoms a clinician can use to diagnose FD, common treatments and the future direction of FD research.
Guest: Karen B. Hirschman, PhD, MSW
Host: Susan Dolan, RN, JD
Is there a best-practice approach to working with families of patients with dementia? Dr. Karen Hirschman, research assistant professor in the department of nursing and a fellow at the Institute on Aging in the Department of Medicine at the University of Pennsylvania joins host Susan Dolan, RN to discuss many aspects of caring for patients with dementia in the hospital and at home. She also shares the progress of the Enhancing Care Coordination Study examining the benefits of home nursing care following a hospital stay for dementia patients.
Guest: Matthew Tominey
Host: Lenard Adler, MD
How can educational accommodations be tailored to best fit ADHD patients? What role does an appropriate psychometric assessment of an ADHD patient play in determining the best educational accommodations for that patient? Do all institutions require similar documentation? Dr. Matthew Tominey, director of Disability Support Services at Seton Hall University, discusses how to best address the educational needs of ADHD patients. Dr. Lenard Adler hosts.
Guest: David Spiegel, MD
Host: Leslie P. Lundt, MD
Several studies have found that over half of all physicians have used placebos in their practice. Is there scientific validity to the prescribing of placebos? Dr. David Speigel, associate chairman of the department of psychiatry and behavioral sciences at the Stanford University School of Medicine, joins host Dr. Leslie Lundt to review the science behind placebos. Dr. Spiegel has extensively studied how psychological factors affect the brain's response to pain and illness.
Host: Anthony Alessi, MD
Guest: Jacqueline A. French, MD
Should special consideration be given to the substitution of antiepileptic drugs, and should antiepileptic prescriptions change for pregnant women? Dr. Jacqueline French, a professor in the department of neurology at the Comprehensive Epilepsy Center at New York University, joins host Dr. Anthony Alessi to discuss how to help determine which is best for your patient, and what key items to review when making the decision. Additionally, Dr. French explores the effect of pregnancy on antiepileptic drugs in women, and in which cases you should advise against antiepileptic drugs during pregnancy.
Guest: Samuel Gandy, MD
Host: Lee Freedman, MD
What medications are approved for the treatment of Alzheimer's disease? Dr. Samuel Gandy, professor and director of the Farber institute for neurosciences at Thomas Jefferson University, discusses state of the art pharmacologic treatments for Alzheimer's disease with host Dr. Lee Freedman. What are the benefits to each medication, and how can physicians prevent side effects from these medications? How do diet and lifestyle influence the condition?
Guest: Justin Sanchez, PhD
Host: Larry Kaskel, MD
Dr. Justin Sanchez explains to host Dr. Larry Kaskel the latest research regarding neuroprosthetics. These prosthetics directly interface and decode brain communications. The greatest development arises in utilizing smart prosthetics called "brain chips" that learn with the patient overtime, and someday may be used routinely to help paralyzed patients control prosthetic limbs with their thoughts. Dr. Sanchez outlines the underlying mechanisms of these devices and the current research within humans. Tune in to hear how these brain-machine interfaces are being used to control prosthetics, and the potential applications to cure diseases such as epilepsy, addiction and Alzheimer's.
Guest: Ann McKee, MD
Host: Mark Nolan Hill, MD
Many elite athletes dedicate their lives to sport. In a high-impact game like football, the physical toll of this dedication can be devastating. One example of this is chronic traumatic encephalopathy, a form of brain damage most commonly linked to boxing. Now, a group of pro football players and other athletes are promising to post-humously donate their brains for research on this condition. Dr. Ann McKee, associate professor of neurology and pathology, and co-director of the Center for the Study of Traumatic Encephalopathy at Boston University School of Medicine, where this research will be conducted, joins host Dr. Mark Nolan Hill to explain the research goals which her team aims to achieve with this inspiring gift.
Guest: Nir Barzilai, MD
Host: Maurice Pickard, MD
What is the role of insulin growth factor in longevity? Dr. Nir Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine and chaired professor of medicine and molecular genetics, speaks about changes in insulin-like growth factor pathways in relation to longevity. The genotype of exceptional age is also associated with improved cognitive function.
Host: Leslie P. Lundt, MD
Guest: David R. Spiegel, MD
Sarcoidosis is a systemic disease most commonly affecting lung, lymph nodes, eyes and skin. Neurosarcoidosis is not an infrequent complication. Host Dr. Leslie Lundt welcomes Dr. David Spiegel, associate professor of clinical psychiatry and behavioral sciences and director of the consultation-liaison service at Eastern Virginia Medical School, to review the diagnosis and treatment of neurosarcoidosis.
Guest: William Hall, MD
Host: Maurice Pickard, MD
Dr. William Hall, director of the Center for Healthy Aging at Highland Hospital in Rochester, New York, discusses with host Dr. Maurice Pickard the unprecedented increase in members of our population age 85 and older, and the role this may play in exceptional longevity. We know more today than we ever have before about disease factors that cause disability and frailty, such as depression, neuromuscular stability, cognitive status and urinary incontinence. How will these factors help to support older patients?
Host: Lee Freedman, MD
Guest: Jason G. Newman, MD, FACS
Minimally-invasive surgery is generally an attractive option, but how reliable and effective is brain surgery performed through the nose? Dr. Jason Newman, assistant professor of otolaryngology - head and neck surgery at the University of Pennsylvania School of Medicine, explores the rapidly evolving field of incisionless brain surgery with host Dr. Lee Freedman. What are the obstacles to approaching brain surgery through the nose, and could there be a robotic component in the next few years?
Guest: Helen Mayberg, MD
Host: Cathleen Margolin, PhD
Dr. Helen Mayberg, professor of psychiatry and neurology at Emory University School of Medicine, joins host Dr. Cathleen Margolin to discuss neural network models of depression. Sharing more than two decades of work in this area, Dr. Mayberg explains how models of mood regulation have led to the development of a new intervention for treatment-resistant patients using deep brain stimulation.
Guest: Jill Jesurum, PhD
Host: Janet Wright, MD
Who would expect that a hole in the heart and a pain in the head are related? If you take care of patients who suffer from migraine headaches, host Dr. Janet Wright's interview with Dr. Jill Jesurum, scientific director of the Heart & Vascular Institute at Swedish Medical Center in Seattle, may shed light on some unanticipated benefits of treatment for migraineurs. Dr. Jesurum explains how patent foramen ovale (PFO) closure may impact the symptoms experienced by a migraine sufferer, and shares her perspective on which populations may benefit most from a PFO procedure.
Guest: Thomas Barr Graboys, MD
Host: Maurice Pickard, MD
Dr. Thomas Graboys, professor of medicine at Harvard Medical School and president emeritus of Lown Cardiovascular Research Foundation in Brookline, Massachusetts, discusses his new book Life in the Balance: a Physician's Memoir of Life, Love and Loss with Parkinson's Disease and Dementia. Dr. Graboys talks to host Dr. Maurice Pickard about his struggles to live with illness without letting illness control his life. He hopes others will find in his story comfort, inspiration, and validation of their own struggles.
Guest: Larry Young, PhD
Host: Leslie P. Lundt, MD
Autism has garnered much attention in recent years. One of the most interesting areas of research is the exploration of oxytocin. Could it improve social interaction? Dr. Larry Young, the William P. Timmie Professor at the Center for Behavioral Neuroscience and the Department of Psychiatry at the Emory University School of Medicine, outlines his latest research with host Dr. Leslie Lundt.
Guest: John Ruge, MD
Host: Bill Rutenberg, MD
Successful brain surgery correlates with the amount of tumor removed. What if the neurosurgeon could visualize the tumor in situ during the operation? Join host, Dr. Bill Rutenberg, and his guest Dr. John Ruge, associate professor of neurosurgery at Rush Medical College and director of the Midwest Children's Brain Tumor Center. Dr. Ruge will discuss the novel technique of fluorescence-guided brain surgery. This technique, used in Germany for 10 years, has recently been brought to the U.S. by Dr. Ruge, who is also the first to apply it in pediatric neurosurgery.
Guest: E. Steve Roach, MD
Host: Jennifer Shu, MD, FAAP
Stroke has been increasingly recognized among children in recent years. Stroke in neonates, in particular, occurs at a much higher rate than in older children. What are the leading risk factors for neonatal stroke? How does it present and how is it diagnosed? Host Dr. Jennifer Shu learns more about the evidence for managing stroke in newborns, as well as the likely short-term and long-term outcomes, from Dr. E. Steve Roach, professor of pediatrics and neurology at the Ohio State University College of Medicine, and chief of the division of child neurology at Nationwide Children's Hospital in Columbus, Ohio.
Guest: Raymond P. Onders, MD
Host: Bruce Bloom, DDS, JD
What is the process required to implant a Diaphragm Pacing System which eliminates the need for ventilator care in ALS patients? Dr. Raymond Onders, director of the Minimally Invasive Surgery at University Hospitals Case Medical Center describes the diagnostic and laparoscopic surgical techniques used to implant a Diaphragm Pacing System that electrically stimulates breathing in spinal cord injury and ALS patients. Hear how this amazing technology changes the lives of patients through a very simple surgery. Hosted by Dr. Bruce Bloom.
Guest: Timothy Coetzee, PhD
Host: Bruce Bloom, DDS, JD
Through a venture philanthropy called Fast Forward, LLC the National Multiple Sclerosis Society plans to deploy 1.5 to 2 million dollars in the next 18 months as seed funding to biotech companies on the path towards cures for Multiple Sclerosis. Our guest, Timothy Coetzee executive director of Fast Forward, LLC joins host Dr. Bruce Bloom to talk about genomics, novel immune system therapies and other hopeful possibilities leading towards cures for multiple sclerosis. Interesting also is the process by which the biotech companies are evaluated and followed after an investment is made.
Guest: Brig. Gen. Loree Sutton, MD
Host: John Armstrong, MD
The physical wounds of a traumatic brain injury are often unmistakable. Yet even mild injury to the brain can bring significant behavioral consequences, which may only surface over time. What are the most common clinical manifestations of these conditions? What can be done to provide suitable therapy? Brig. Gen. Dr. Loree Sutton, director of the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, shares her expertise with host Dr. John Armstrong.